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A B S T R A C T
Background
Health outcomes are improved when newborn babies with critical congenital heart defects (CCHDs) are detected before acute car-
diovascular collapse. The main screening tests used to identify these babies include prenatal ultrasonography and postnatal clinical
examination; however, even though both of these methods are available, a significant proportion of babies are still missed. Routine
pulse oximetry has been reported as an additional screening test that can potentially improve detection of CCHD.
Objectives
• To determine the diagnostic accuracy of pulse oximetry as a screening method for detection of CCHD in asymptomatic newborn
infants
• To assess potential sources of heterogeneity, including:
© characteristics of the population: inclusion or exclusion of antenatally detected congenital heart defects;
© timing of testing: < 24 hours versus ≥ 24 hours after birth;
© site of testing: right hand and foot (pre-ductal and post-ductal) versus foot only (post-ductal);
© oxygen saturation: functional versus fractional;
© study design: retrospective versus prospective design, consecutive versus non-consecutive series; and
© risk of bias for the “flow and timing” domain of QUADAS-2.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 2) in the Cochrane Library and the following
databases: MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Health Services
Research Projects in Progress (HSRProj), up to March 2017. We searched the reference lists of all included articles and relevant
systematic reviews to identify additional studies not found through the electronic search. We applied no language restrictions.
1Pulse oximetry screening for critical congenital heart defects (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Selection criteria
We selected studies that met predefined criteria for design, population, tests, and outcomes. We included cross-sectional and cohort
studies assessing the diagnostic accuracy of pulse oximetry screening for diagnosis of CCHD in term and late preterm asymptomatic
newborn infants. We considered all protocols of pulse oximetry screening (eg, different saturation thresholds to define abnormality,
post-ductal only or pre-ductal and post-ductal measurements, test timing less than or greater than 24 hours). Reference standards
were diagnostic echocardiography (echocardiogram) and clinical follow-up, including postmortem findings, mortality, and congenital
anomaly databases.
Data collection and analysis
We extracted accuracy data for the threshold used in primary studies. We explored between-study variability and correlation between
indices visually through use of forest and receiver operating characteristic (ROC) plots. We assessed risk of bias in included studies using
the QUADAS-2 tool. We used the bivariate model to calculate random-effects pooled sensitivity and specificity values. We investigated
sources of heterogeneity using subgroup analyses and meta-regression.
Main results
Twenty-one studies met our inclusion criteria (N = 457,202 participants). Nineteen studies provided data for the primary analysis
(oxygen saturation threshold < 95% or ≤ 95%; N = 436,758 participants). The overall sensitivity of pulse oximetry for detection of
CCHD was 76.3% (95% confidence interval [CI] 69.5 to 82.0) (low certainty of the evidence). Specificity was 99.9% (95% CI 99.7
to 99.9), with a false-positive rate of 0.14% (95% CI 0.07 to 0.22) (high certainty of the evidence). Summary positive and negative
likelihood ratios were 535.6 (95% CI 280.3 to 1023.4) and 0.24 (95% CI 0.18 to 0.31), respectively. These results showed that out of
10,000 apparently healthy late preterm or full-term newborn infants, six will have CCHD (median prevalence in our review). Screening
by pulse oximetry will detect five of these infants as having CCHD and will miss one case. In addition, screening by pulse oximetry
will falsely identify another 14 infants out of the 10,000 as having suspected CCHD when they do not have it.
The false-positive rate for detection of CCHD was lower when newborn pulse oximetry was performed longer than 24 hours after
birth than when it was performed within 24 hours (0.06%, 95% CI 0.03 to 0.13, vs 0.42%, 95% CI 0.20 to 0.89; P = 0.027).
Forest and ROC plots showed greater variability in estimated sensitivity than specificity across studies. We explored heterogeneity by
conducting subgroup analyses and meta-regression of inclusion or exclusion of antenatally detected congenital heart defects, timing of
testing, and risk of bias for the “flow and timing” domain of QUADAS-2, and we did not find an explanation for the heterogeneity in
sensitivity.
Authors’ conclusions
Pulse oximetry is a highly specific and moderately sensitive test for detection of CCHD with very low false-positive rates. Current
evidence supports the introduction of routine screening for CCHD in asymptomatic newborns before discharge from the well-baby
nursery.
P L A I N L A N G U A G E S U M M A R Y
Pulse oximetry for diagnosis of critical congenital heart defects
Review question
We reviewed evidence on the accuracy of pulse oximetry for detection of critical congenital heart defects (CCHDs) in asymptomatic
newborn infants.
Background
CCHDs occur in around two in 1000 newborn infants and are a leading cause of infant death. Timely diagnosis is crucial for best
outcomes for these babies, but current screening methods may miss up to 50% of affected newborn infants before birth, and those sent
home before diagnosis frequently die or endure major morbidity. However, babies with CCHD often have low blood oxygen levels,
which can be detected quickly and non-invasively by pulse oximetry, using a sensor placed on the newborn infant’s hand or foot. A pulse
oximeter is a machine that can measure, non-invasively, the amount of oxygen carried around the body by red blood cells. Oxygen from
the lungs is bound to hemoglobin in red blood cells, forming oxyhemoglobin. If oxygen is not bound, de-oxyhemoglobin is formed. In
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health, almost all hemoglobin is oxyhemoglobin, and so oxygen saturation (ie, the percentage of hemoglobin that has bound oxygen) is
close to 100%. The pulse oximeter measures this by passing light through peripheral blood vessels (eg, a fingertip in an adult, in a hand
or foot in a baby). Oxyhemoglobin and de-oxyhemoglobin absorb this light in different ways, and the proportion of light absorbed
can be analyzed by software within the oximeter, which then calculates the percentage of hemoglobin saturated with oxygen.
Study characteristics
We searched until March 2017 for evidence on use of pulse oximetry to detect CCHD in newborn infants and found 21 studies. These
studies used different thresholds to define a pulse oximetry test as positive. We combined all studies using a threshold around 95% (19
studies with 436,758 newborn infants).
Key results
This review found that for every 10,000 apparently healthy newborn infants screened, around six of them will have CCHD. The pulse
oximetry test will correctly identify five of these newborn infants with CCHD (but will miss one case). Newborn infants who are missed
could die or experience major morbidity.
For every 10,000 apparently healthy newborn infants screened, 9994 will not have CCHD. The pulse oximetry test will correctly
identify 9980 of them (but 14 newborn infants will be investigated for suspected CCHD). Some of these infants may be exposed to
unnecessary additional tests and a prolonged hospital stay, but a proportion will have a potentially serious non-cardiac illness.
The number of newborn infants incorrectly investigated for CCHD decreases when pulse oximetry is performed longer than 24 hours
after birth.
Certainty of evidence
We judged the included studies to be mainly at low or unclear risk of bias for several of the certainty domains assessed. Some studies
used less robust methods to verify negative results. We considered the overall certainty of the evidence as moderate.
B A C K G R O U N D
Congenital heart defects (CHDs) constitute the most common
group of congenital malformations, with an incidence of 4 to
10 per 1000 live births (Botto 2001; Lloyd-Jones 2009; Mahle
2009; Wren 2008); they account for more deaths than any other
congenital malformation (Heron 2007; Mahle 2009; Office of
National Statistics, 2015), and up to 10% of all infant deaths
are attributed to them (Abu-Harb 1994; Boneva 2001; Knowles
2005; Lloyd-Jones 2009; Wren 2008). Life-threatening critical
CHDs (CCHDs) account for approximately 15% to 25% of all
CHDs (Mahle 2009; Wren 2008). Most CCHDs are amenable
to treatment, but poor clinical condition at the time of surgery
increasesmortality andhas been shown to result inworse outcomes
for conditions such as hypoplastic left heart (Brown 2001; Brown
2006), coarctation of the aorta (Franklin 2002), and transposition
of the great arteries (Tworetzky 2001). Early detection of these
conditions can reduce the risk of acute cardiovascular collapse and
death (Abu-Harb 1994; Mahle 2009).
Most newborns with a CCHD are asymptomatic at birth (Wren
2008); detection before the onset of symptoms usually involves
routine screening by antenatal ultrasound scan, as described by
Allan 1986 and Bull 1999, and by postnatal clinical examination
of the cardiovascular system, as reported by Hall 1999. Unfor-
tunately, both methods have a variable, and often low, detection
rate (Abu-Harb 1994a; Carvalho 2002; Chew 2007; Garne 2001;
Tegnander 2006;Westin 2006;Wren 1999), and up to 30% of in-
fants born with CCHDs are discharged home before the diagnosis
has been established (Abu-Harb 1994; Brown 2006; Mellander
2006; Wren 2008), with reported mortality rates as high as 50%
(Chang 2008).
Although antenatal detection rates following screeningultrasonog-
raphy are improving, average detection of isolated CCHD remains
less than 50% (Abu-Harb 1994a; Carvalho 2002; Chew 2007;
Garne 2001; Tegnander 2006; Westin 2006; Wren 1999). Clini-
cal examination abnormalities such as murmur and weak pulse are
often absent in early postnatal life, and the more common find-
ing of cyanosis (bluish discoloration of the skin due to reduced
oxygen in the blood) is frequently clinically undetectable (Mahle
2008; O’Donnell 2007). The fact that most infants with CCHD
will have such mild cyanosis has led to the exploration of pulse
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oximetry assessment as a possible screening test to identify affected
infants (Ewer 2012a; Knowles 2005; Lloyd-Jones 2009).
Following publication of several large test accuracy studies, several
countries adopted pulse oximetry screening as routine practice,
andmanymore are considering its introduction (de-WahlGranelli
2014; Ewer 2014; Kuelling 2009; Mahle 2012; Manzoni 2017).
In addition to test accuracy, studies have demonstrated that pulse
oximetry screening is cost-effective (Knowles 2005; Peterson2013;
Roberts 2012), and that it is acceptable to both parents and clinical
staff (Narayen 2017; Powell 2013).
The vast majority of babies studied have been screened in a hos-
pital setting - specifically, the well-baby nursery - at low altitude.
However, screening has been reported recently in other settings
including neonatal units (Iyengar 2014; Suresh 2013), as well as
out of hospital settings such as home births - reported by Cawsey
2016; Lhost 2014; and Narayen 2016a - and births at moderate
altitude (Han 2013; Wright 2014).
This reviewdoes not include settings outside thewell-baby nursery.
Target condition being diagnosed
The definition of CCHD is not consistent, and the literature re-
veals many interpretations (Ewer 2012a). One of the difficulties
arises because some conditions (such as coarctationof the aorta and
pulmonary stenosis) may or may not predispose to acute collapse,
depending on relative severity. For the purposes of this review,
we have used a previously described definition of CCHD, that is,
“any potentially life-threatening duct-dependent heart lesion from
which infants either die or require invasive procedures (surgery or
cardiac catheterization) in the first 28 days of life” (Ewer 2012a;
Wren 2008). The definition includes all infants with hypoplastic
left heart syndrome, pulmonary atresia with intact ventricular sep-
tum, simple transposition of the great arteries, or interruption of
the aortic arch. In addition, all infants dying or needing surgery
or catheter in the first 28 days of life with coarctation of the aorta,
aortic valve stenosis, pulmonary valve stenosis, tetralogy of Fallot,
pulmonary atresia with ventricular septal defect, or total anoma-
lous pulmonary venous connection are classified as having critical
congenital heart defects. This definition offers the advantages that
it allows a degree of assessment of severity of certain lesions based
on early death or intervention, it is relatively easy to categorize,
and it has been used in several test accuracy studies and previ-
ous systematic reviews (Ewer 2011; Ewer 2012a; Thangaratinam
2012; Zhao 2014).
Index test(s)
Pulse oximetry measurement of oxygen saturations in an asymp-
tomatic newborn infant can be used to identify CCHD before
discharge from hospital. Pulse oximetry is an accurate and well-
established test used to quantify hypoxemia (low oxygen levels in
the blood) that is rapid, painless, and easy to perform in all pa-
tient groups including newborn infants (Ewer 2012a; Ewer 2013;
Knowles 2005; Lloyd-Jones 2009; Mahle 2009; Narayen 2016b).
Any trained individual can perform pulse oximetry screening, and
results can be obtained in approximately five minutes. For infants
enrolled in pulse oximetry screening studies, pulse oximetry probes
(to measure oxygen saturations) are placed on the foot only (post-
ductal) or on the right hand and foot (pre-ductal and post-duc-
tal) (Ewer 2012b; Ewer 2013; Ewer 2016). The index test allows
screening to reduce the number of infants discharged from hos-
pital before diagnosis of CCHD, and it can be performed at any
point before discharge before or after the clinical examination.
Clinical pathway
Standard screening for CCHD usually includes midtrimester ul-
trasonography of pregnant women, which includes assessment of
fetal cardiac anatomy. If a cardiac defect is suspected when this
examination is performed, a detailed fetal echocardiogram may
confirm the diagnosis. Most newborn infants also undergo one
or more clinical examinations before discharge from the hospital,
which include assessment of the cardiovascular system (ausculta-
tion of heart sounds, palpation of peripheral pulses). If a cardiac
defect is suspected upon completion of either of these screening
tests, then a postnatal diagnostic echocardiogram is usually ob-
tained. As described previously, these screening tests have variable,
and often low, detection rates.
The population included in this review may or may not have had
antenatal screening. All were asymptomatic at the time of pulse
oximetry screening.
Alternative test(s)
In addition to the screening tests already described, alternatives
such as routine screening fetal echocardiography and postnatal
echocardiography have been proposed but are unlikely to be cost-
effective (Knowles 2005). This reviewdidnot assess the accuracy of
existing screening tests (ie, antenatal ultrasonography and physical
examination).
Rationale
Hypoxemia, or suboptimal arterial oxygen saturation, is present
in most infants with CCHD (Ewer 2012a; Lloyd-Jones 2009;
Mahle 2009). Some may have overt cyanosis, but in many, the
degree of hypoxaemia may be difficult to discern on clinical ex-
amination. Pulse oximetry is a quick, painless, non-invasive, and
reliable method used to determine arterial oxygen saturation lev-
els; it has been widely used in many areas of clinical medicine
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for over 30 years. The concept of using oxygen saturations as a
screen for critical heart defects was first reported more than 15
years ago. Pulse oximetry screening may allow detection of infants
who have been missed by other screening methods before they
are discharged from hospital, allowing urgent cardiac intervention
before the onset of life-threatening cardiorespiratory collapse. Sys-
tematic reviews of pulse oximetry screening studies have been pub-
lished (Thangaratinam 2007; Thangaratinam 2012), and indeed
this screening technique is now common practice in the United
States and in some European countries. However, this is the only
review that includes recent large test accuracy studies, including
one reported from a middle-income country - China.
We performed a systematic review of studies assessing the diagnos-
tic accuracy of screening with pulse oximetry (index test) in rela-
tion to echocardiography or clinical follow-up (reference standard)
for detection of CCHD in asymptomatic newborn infants. It is
important to note that we wanted to determine how well a nega-
tive pulse oximetry test result rules out a CCHD diagnosis. Sev-
eral previous reviews have explored this topic (Ewer 2012a; Ewer
2013; Knapp 2010; Knowles 2005; Lloyd-Jones 2009; Narayen
2016b; Thangaratinam 2007).
O B J E C T I V E S
• To determine the diagnostic accuracy of pulse oximetry as a
screening method for detection of CCHD in asymptomatic
newborn infants
Secondary objectives
• To assess potential sources of heterogeneity, including:
◦ characteristics of the population: inclusion or
exclusion of antenatally detected congenital heart defects;
◦ timing of testing: < 24 hours versus ≥ 24 hours after
birth;
◦ site of testing: right hand and foot (pre-ductal and
post-ductal) versus foot only (post-ductal);
◦ oxygen saturation: functional versus fractional;
◦ study design: retrospective versus prospective design,
consecutive versus non-consecutive series; and
◦ risk of bias for the “flow and timing” domain of
QUADAS-2.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered inclusion of prospective or retrospective cohort and
cross-sectional studies evaluating the diagnostic accuracy of pulse
oximetry as a screening method for detection of critical congeni-
tal heart defects in asymptomatic newborn infants. A study of di-
agnostic accuracy should provide sufficient data for construction
of the two-by-two table showing the cross-classification of disease
status (CCHD) and test outcome (pulse oximetry). We excluded
studies if we could not extract true-positive (TP), true-negative
(TN), false-positive (FP), and false-negative (FN) values after con-
tacting corresponding authors of primary studies when necessary.
We excluded case reports and studies of case-control design.
Participants
We included studies that recruited asymptomatic (with no signs of
respiratory or cardiac illness) term or near-term newborns before
discharge from hospital.
Index tests
The test under evaluation was pulse oximetry screening to identify
low oxygen saturation. We included all protocols of screening (eg,
post-ductal [foot] only vs pre-ductal and post-ductal [right hand
and foot], different saturation thresholds to define abnormality,
different numbers of repeat tests). Criteria for defining a screen as
positive or negative in this review were those used by the authors
of respective publications.
Target conditions
Critical congenital heart defects as defined above.
Reference standards
Reference standards were diagnostic echocardiography (echocar-
diogram) and clinical follow-up in the first 28 days of life, in-
cluding postmortem findings and information frommortality and
congenital anomaly databases, to identify patients with false-neg-
ative findings.
Search methods for identification of studies
Electronic searches
Information Specialists of the Cochrane Neonatal Review Group
performed the searches. Using the strategy described in Appendix
1, they searched the following databases.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 2) in the Cochrane Library.
• MEDLINE via PubMed (1966 to March 2017).
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• Embase via Ovid (1980 to March 2017).
• Cumulative Index to Nursing and Allied Health Literature
(CINAHL) (1982 to March 2017).
TheMEDLINE search strategy includedmedical subject headings
(MeSH) and free text words (see Appendix 1). We adjusted this
strategy for use with the other electronic databases. We consid-
ered a combination of medical subject headings and text terms to
generate three subsets of citations: one subset indexing the index
test (pulse oximetry), a second subset indexing the target popu-
lation (infant-newborn), and a third subset indexing the clinical
condition (congenital heart disease). We combined these subsets
to generate a set of citations relevant to our research question. We
considered both published and unpublished reports for inclusion
and excluded studies published in abstract form only. We applied
no language restriction to the electronic searches.
Searching other resources
We used the Science Citation Index, accessed via the Institute for
Scientific Information (ISI) Web of Science, to retrieve reports
citing the studies included in this review. We searched for sim-
ilar systematic reviews in the Database of Abstracts of Reviews
of Effects (DARE) to March 2017, to cross-reference results. We
also searched the Health Services Research Projects in Progress
(HSRProj) database (http://www.nlm.nih.gov/hsrproj/) (searched
on March 20, 2017). We handsearched the reference lists of all
relevant primary studies on the topic of our interest to identify
cited articles not captured by our electronic searches (up to March
15, 2017). We applied no language restrictions.
Data collection and analysis
Selection of studies
Two review authors (MNP and JZ) independently screened ti-
tles and abstracts identified through electronic literature searches
to identify potentially eligible studies. First, we excluded those
records classified by both review authors as “excluded.” Second, we
independently assessed the full text of reports classified as “unsure”
or “potentially eligible” by applying the selection criteria outlined
above in the Criteria for considering studies for this review sec-
tion. We resolved disagreements through discussion. If finally we
reached no consensus, we consulted a third review author (AKE).
Data extraction and management
We used a standardized data extraction form to aid extraction of
relevant information and data from each included study. Three re-
view authors (MNP, LFP, and AKE) separately participated in data
extraction. MNP and LFP extracted data corresponding to study
design, participant details, method of testing, threshold saturation
level, and type of oxygen saturation measured, as well as timing
of the test and inclusion or exclusion of infants with suspected
congenital heart defects after antenatal ultrasound screening in
pregnancy, reference tests, and funding. AKE and MNP extracted
the following data to reconstruct the two-by-two table: true-pos-
itive, false-positive, true-negative, and false-negative values or, if
not available, relevant parameters (sensitivity, specificity, or pos-
itive and negative predictive values). Two review authors (MNP
and JZ) incorporated data and study characteristics into Review
Manager 5.3 (RevMan 2014).
Dealing with duplicate publications
We included only once those studies that have been published
in duplicate, ensuring that we extracted all relevant data from all
publications.
Inconclusive results
Although we did not anticipate uninterpretable results, when we
detected these cases, we excluded them from analysis and ade-
quately reported their frequency in tables.
Assessment of methodological quality
Two review authors (MNP and LFP) independently appraised
the methodological quality of each included study using the
QUADAS-2 tool (Whiting 2011). QUADAS-2 consists of four
domains, each requiring a risk of bias categorization of low, high,
or unclear risk. The first three domains are also assessed in terms
of concerns about applicability (applicability concerns ratings).
Each domain comprises a set of signaling questions that should
be marked as “yes,” “no,” or “unclear.” We tailored QUADAS-2
for our specific review question by modifying signaling questions
accordingly and providing guidance on how to assess risk of bias
and applicability concerns ratings (Appendix 2). We resolved dis-
agreements between risk of bias and applicability concern ratings
through discussion or by consultation with a third review author
(AKE).We summarized our results in the text and in tables and cor-
responding figures. We decided post hoc to assess the certainty of
evidence by using the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach (GRADEpro
GDT; Hultcrantz 2017; Schunemann 2008).
Statistical analysis and data synthesis
We performed analyses using methods described in Chapter 10
of the Cochrane Handbook for Systematic Reviews of Diagnostic Test
Accuracy (Macaskill 2010).
We considered pulse oximetry screening as positive if the oxygen
saturation level was below the threshold defined in the primary
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study, and negative if it was above that threshold. Cross-classifi-
cation of these test results with those of the reference standard(s)
produced the numbers of true positives, false positives, true neg-
atives, and false negatives for each study, based on the ability of
pulse oximetry to detect CCHD.
We used data from the two-by-two tables to calculate sensitivity
and specificity for individual studies. We present individual study
results by plotting the estimates of sensitivity and specificity (and
their 95% confidence intervals) in both forest plots and receiver
operating characteristic (ROC) scatter plots. We extracted accu-
racy data for the threshold used in primary studies.
We performed meta-analyses using a bivariate model (Chu 2006;
Reitsma 2005). This model accounts for intra-study accuracy vari-
ability and inter-study variations in test performance with inclu-
sion of random effects. We analyzed studies sharing the same
threshold and obtained summary accuracy estimates (when the
number of studies was enough). We present these estimates with
a 95% confidence ellipse in the ROC space. We used pooled esti-
mates of sensitivity and specificity to derive positive and negative
likelihood ratios that can be used to update the prior probability
of having CCHD to a post-test probability of having CCHD after
a positive or negative pulse oximetry result. The greater the pos-
itive likelihood ratio and the lower the negative likelihood ratio,
the more important the effect of the test on changing pretest into
post-test probabilities. We did not calculate positive and negative
predictive values because these indices depend on the prevalence
of the target condition (ie, CCHD).
For analyses, we used a METADAS SAS macro that estimates pa-
rameters for the model with SAS Proc NLMIXED (SAS Institute
Inc. 2004; Takwoingi 2010).We entered parameter estimates from
the bivariate model into RevMan to produce the summary oper-
ating point with a 95% confidence region and a 95% prediction
region (Chu 2006; Reitsma 2005; RevMan 2014).
Investigations of heterogeneity
We explored between-study variability and correlation between
indices visually through forest and ROC plots. We measured
total between-study variability in sensitivity and in specificity
through variances of the random effects for logit(sensitivity),
logit(specificity), and their covariance of the bivariate model. We
also provided confidence and prediction ellipses. We further in-
vestigated heterogeneity by exploring effects of several study-level
factors through subgroup and meta-regression analyses including
covariate terms to the bivariate model (Chu 2006; Reitsma 2005).
When available, we examined the following covariates.
• Inclusion or exclusion of antenatally detected congenital
heart defects.
• Screening test method (the screening test may be performed
at different times after birth, oxygen saturations may be
measured at pre-ductal and post-ductal sites or at post-ductal
sites only, and, finally, the oxygen saturation measured could be
expressed as “functional” [which refers to the proportion of
oxygenated hemoglobin that is capable of binding oxygen] or
“fractional” [which refers to the percentage of total hemoglobin
that is oxygenated]). In most cases, differences between the two
values are very small, and most modern pulse oximeters measure
functional saturations only.
• Study design (included studies may be prospective or
retrospective, and may enroll consecutive patients or not). We
expect that retrospective studies are more prone to information
and selection biases. In this review, it is more likely that medical
records of infants with a positive index test result include more
information as compared with medical records of infants with a
negative test result (information bias). In a similar way, infants
with any CCHD are more likely than infants without CCHD to
be detected and included in the study after a retrospective
medical records review (selection bias).
• Risk of bias of the “flow and timing” domain of the
QUADAS-2 questionnaire (unclear/high vs low risk of bias). It is
expected that studies used different reference standards to
confirm index test results (echocardiogram, clinical follow-up,
registries in mortality, and congenital anomaly databases).
Sensitivity analyses
We examined the robustness of meta-analyses by conducting sen-
sitivity analyses. We checked the impact of excluding studies from
analysis according to domains of the QUADAS-2 assessment. Ad-
ditionally, we decided to perform ad hoc sensitivity analyses to ex-
plore how sensitivity and specificity vary by including or excluding
studies with different thresholds.
Assessment of reporting bias
We did not investigate reporting bias, given the limited power of
available tests and uncertainty about interpreting statistical evi-
dence of funnel plot asymmetry as necessarily implying publica-
tion bias (Leeflang 2008).
R E S U L T S
Results of the search
Figure 1 shows details of the search and selection process. Elec-
tronic database searches yielded a total of 3415 references from
CENTRAL, MEDLINE, Embase, and CINAHL. Searches for
primary studies through other resources did not reveal additional
potentially eligible studies.
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Figure 1. Flow of studies through the screening process. CCHD: critical congenital heart defect.
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After de-duplication, two review authors (MNP and JZ) indepen-
dently assessed 2695 references against the inclusion criteria. Dur-
ing initial screening of titles and abstracts, we identified 56 stud-
ies (46 full-text papers and 10 conference abstracts). We excluded
2639 references because they did not meet the inclusion criteria.
We also excluded those published in abstract form only (n = 10).
Of 46 full-text studies, nine studies provided a partial two-by-two
diagnostic table, and we excluded them. We excluded 17 other
studies for the following reasons.
• Different outcomes (not accuracy) (n = 6).
• Inability to determine CCHD outcomes (n = 1).
• Out-of-hospital births (n = 2).
• Preliminary studies (n = 1).
• Different population (n = 2).
• Health technology assessment report on already included
study (n = 1).
• Case-control study (n = 1).
• Journal club (n = 1).
• Case report (n = 1).
• Different index test (n = 1) (see Characteristics of excluded
studies).
We obtained one additional study by searching Science Citation
Index (Gomez-Rodriguez 2015). We included 21 studies in a
quantitative synthesis (Arlettaz 2006; Bakr 2005; Bhola 2014;
de-Wahl Granelli 2009; Ewer 2011; Gomez-Rodriguez 2015;
Jones 2016; Klausner 2017; Koppel 2003; Meberg 2008; Oakley
2015; Ozalkaya 2016; Richmond 2002; Riede 2010; Rosati 2005;
Sendelbach 2008; Singh 2014; Turska 2012; Van Niekerk 2016;
Zhao 2014; Zuppa 2015).
Characteristics of studies
We provide in the Characteristics of included studies table details
on the design, setting, population, index test, target condition,
and reference standard of all included studies. We prepared an
additional table (Table 1) to summarize the main characteristics.
Of 3415 references, we identified 21 primary studies that were eli-
gible for inclusion and provided data for 457,202 newborn infants
(Figure 1). Studies were published between 2002 and 2017. Coun-
tries included were United Kingdom (Ewer 2011; Jones 2016;
Oakley 2015; Richmond 2002; Singh 2014), Italy (Rosati 2005;
Zuppa 2015), USA (Klausner 2017; Koppel 2003; Sendelbach
2008), Australia (Bhola 2014), China (Zhao 2014), Germany (
Riede 2010),Mexico (Gomez-Rodriguez 2015), Norway (Meberg
2008), Poland (Turska 2012), Saudi Arabia (Bakr 2005), South
Africa (Van Niekerk 2016), Sweden (de-Wahl Granelli 2009),
Switzerland (Arlettaz 2006), and Turkey (Ozalkaya 2016).
Sixteen studies included prospective cohorts (Arlettaz 2006; Bakr
2005; de-Wahl Granelli 2009; Ewer 2011; Gomez-Rodriguez
2015; Koppel 2003; Meberg 2008; Oakley 2015; Richmond
2002; Riede 2010; Rosati 2005; Sendelbach 2008; Turska 2012;
Van Niekerk 2016; Zhao 2014; Zuppa 2015), as well as five
retrospective cohorts (Bhola 2014; Jones 2016; Klausner 2017;
Ozalkaya 2016; Singh 2014). Seventeen studies excluded new-
borns who were suspected to have congenital heart disease af-
ter antenatal ultrasound screening during pregnancy (Bakr 2005;
de-Wahl Granelli 2009; Gomez-Rodriguez 2015; Jones 2016;
Klausner 2017; Koppel 2003; Meberg 2008; Oakley 2015;
Ozalkaya 2016; Riede 2010; Rosati 2005; Sendelbach 2008; Singh
2014; Turska 2012; Van Niekerk 2016; Zhao 2014; Zuppa 2015)
(Table 1).
Nine studies performed pulse oximetry within 24 hours after birth
(Arlettaz 2006; Ewer 2011; Gomez-Rodriguez 2015; Jones 2016;
Meberg 2008; Richmond 2002; Sendelbach 2008; Singh 2014;
Turska 2012) (Table 1). Twelve studies used the foot alone (post-
ductal) tomeasure oxygen saturation, and the remainder used both
right hand and foot (pre-ductal and post-ductal) (Table 1). Inves-
tigators used several different pulse oximeter models (see descrip-
tion in Table 1). Two studies measured fractional saturations (Bakr
2005; Richmond 2002) (Table 1). Eight studies used a post-ductal
saturation threshold of less than 95% (Arlettaz 2006; Bhola 2014;
Gomez-Rodriguez 2015; Meberg 2008; Oakley 2015; Richmond
2002; Turska 2012; Zuppa 2015), three studies used a post-ductal
saturation threshold ≤ 95% (Koppel 2003; Riede 2010; Rosati
2005), and six studies used both pre-ductal and post-ductal satura-
tions less than 95% (de-Wahl Granelli 2009; Ewer 2011; Klausner
2017; Singh 2014; Van Niekerk 2016; Zhao 2014). Two stud-
ies reported different positive thresholds (Bakr 2005 reported
both pre-ductal and post-ductal fractional saturation ≤ 94%, and
Sendelbach 2008 reported post-ductal saturation < 96%) (Table
1). In summary, the most common threshold was less than 95%
(n = 14); five studies reported a threshold lower than or equal to
95%, and two studies reported thresholds≤ 94% and < 96%, re-
spectively. No study reported results for more than one threshold.
Studies used different methods to verify test results: Investigators
verified positive test results by echocardiography and negative re-
sults by interrogation of congenital anomaly registers, mortality
data, or clinical follow-up (Table 1).
Methodological quality of included studies
We appraised the quality of primary diagnostic accuracy studies
using the QUADAS-2 tool. We present quality assessment results
for individual studies in the Characteristics of included studies
table and in Figure 2. We have summarized the overall risk of bias
and applicability concerns of studies in Figure 3.
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Figure 2. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study.
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Figure 3. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies.
We judged the risk that patient selection (QUADAS-2, domain
1) had introduced bias as low in 10 studies (Arlettaz 2006; Bakr
2005; de-Wahl Granelli 2009; Ewer 2011; Jones 2016; Klausner
2017; Koppel 2003; Ozalkaya 2016; Richmond 2002; Zuppa
2015), high in two because investigators did not avoid inappropri-
ate exclusions (Oakley 2015; Van Niekerk 2016), and unclear in
the remaining nine studies (Bhola 2014; Gomez-Rodriguez 2015;
Meberg 2008; Riede 2010; Rosati 2005; Sendelbach 2008; Singh
2014; Turska 2012; Zhao 2014). Applicability was of low concern
for all studies in the patient selection domain.
For the index test assessment (QUADAS-2, domain 2), we consid-
ered all studies to be at low risk of bias and low concern regarding
applicability.
We judged the risk that conduct or interpretation of reference
standard(s) (QUADAS-2, domain 3) had introduced bias as low in
four studies because investigators used echocardiography to con-
firm both positive and negative pulse oximetry cases (Ozalkaya
2016), or because they used echocardiography to confirm pulse
oximetry positives and clinical follow-up in the first 28 days of
life, which included postmortem findings and mortality and con-
genital anomaly databases to identify false-negative screening cases
(Ewer 2011; Koppel 2003; Turska 2012). This comprehensive
combination of clinical follow-up and review of registries and
databases was considered as having low risk of bias. We considered
that three studies reporting only echocardiography as the reference
standard for positive pulse oximetry results were at high risk of bias
(Arlettaz 2006; Van Niekerk 2016; Zuppa 2015). We considered
risk for the remaining 14 studies as unclear because they used an
incomplete reference standard to identify false-negative cases (Bakr
2005; Bhola 2014; de-Wahl Granelli 2009; Gomez-Rodriguez
2015; Jones 2016; Klausner 2017; Meberg 2008; Oakley 2015;
Richmond 2002; Riede 2010; Rosati 2005; Sendelbach 2008;
Singh 2014; Zhao 2014); six studies used echocardiography
and follow-up (Gomez-Rodriguez 2015; Klausner 2017; Meberg
2009; Rosati 2005; Sendelbach 2008; Zhao 2014), and eight stud-
ies used echocardiography and different mortality and malforma-
tions registries (Bakr 2005; Bhola 2014; de-Wahl Granelli 2009;
Jones 2016; Oakley 2015; Richmond 2002; Riede 2010; Singh
2014). It is noteworthy that only one study used echocardiography
for positive and negative pulse oximetry results (Ozalkaya 2016).
Applicability was of low concern for all studies in the reference
standard(s) domain.
For flow and timing assessment (QUADAS-2, domain 4), 11 stud-
ies were at low risk of bias (de-Wahl Granelli 2009; Ewer 2011;
Gomez-Rodriguez 2015; Koppel 2003; Meberg 2008; Oakley
2015; Ozalkaya 2016; Richmond 2002; Riede 2010; Singh 2014;
Zhao 2014), and the remaining studies were at unclear risk be-
cause information reported was insufficient to permit judgment
(Arlettaz 2006; Bakr 2005; Bhola 2014; Jones 2016; Klausner




We considered for primary analysis all studies with thresholds
around 95% (< 95% and ≤ 95%). As expected, this was the
most common threshold among included studies (n = 19 stud-
ies; 436,758 participants) (Arlettaz 2006; Bhola 2014; de-Wahl
Granelli 2009; Ewer 2011; Gomez-Rodriguez 2015; Jones 2016;
Klausner 2017; Koppel 2003; Meberg 2008; Oakley 2015;
Ozalkaya 2016; Richmond 2002; Riede 2010; Rosati 2005; Singh
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2014; Turska 2012; VanNiekerk 2016; Zhao 2014; Zuppa 2015).
The overall sensitivity of pulse oximetry for detection of critical
congenital heart defects was 76.3% (95% confidence interval [CI]
69.5 to 82.0). Specificity was 99.9% (95% CI 99.7 to 99.9) with
a false-positive rate of 0.14% (95% CI 0.07 to 0.22) (Summary of
findings). Summary positive and negative likelihood ratios were
535.6 (95%CI 280.3 to 1023.4) and 0.24 (95%CI 0.18 to 0.31),
respectively.
Fourteen out of 19 studies used a threshold lower than 95% (
Arlettaz 2006; Bhola 2014; de-Wahl Granelli 2009; Ewer 2011;
Gomez-Rodriguez 2015; Klausner 2017; Meberg 2008; Oakley
2015; Richmond 2002; Singh 2014; Turska 2012; Van Niekerk
2016; Zhao 2014; Zuppa 2015), and five studies used a threshold
lower than or equal to 95% (Jones 2016; Koppel 2003; Ozalkaya
2016; Riede 2010; Rosati 2005).
Two additional studies used different thresholds: One used a
threshold lower than or equal to 94% with sensitivity and speci-
ficity of 100% (95% CI 29 to 100) and 100% (95% CI 100 to
100), respectively (Bakr 2005); the other used a threshold of less
than 96% with sensitivity and specificity of 100% (95% CI 3 to
100) and 100% (95% CI 100 to 100), respectively (Sendelbach
2008).
Overall, we have included in this review 349 cases of CCHD. The
median prevalence of CCHD was 0.6 per 1000 live births (range
0.1 to 3.7; interquartile range 0.4 to 1.2).
Investigations of heterogeneity
Tovisualize total variability in sensitivity and specificity, we present
the data in forest and ROC scatter plots (Figure 4; Figure 5). Forest
plots show studies in increasing order of specificity (Figure 4). Sen-
sitivity of the 21 studies ranged from 0% to 100%, and specificity
from 99% to 100%. Forest and ROC plots show greater variabil-
ity in estimated sensitivity than specificity across studies. Given
results from investigations of heterogeneity, we used the bivariate
model to estimate summary sensitivity and specificity (summary
points) instead of the hierarchical summary ROC model to esti-
mate summary ROC curves.
Figure 4. Forest plot of sensitivity and specificity. The figure shows the estimated sensitivity and specificity
of the study (blue square) and its 95% confidence interval (black horizontal line). Studies are ordered by
ascending specificity.
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Figure 5. Summary ROC plot for pulse oximetry using a threshold lower than or lower than or equal to 95%
(n = 19 studies). The solid circle corresponds to the summary estimate of sensitivity and specificity, and is
shown with a 95% prediction region (dashed line).
13Pulse oximetry screening for critical congenital heart defects (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
For the primary analysis, we measured total between-study vari-
ability in sensitivity and in specificity through variances of the ran-
dom effects for logit(sensitivity), logit(specificity), and their co-
variance, which were 0.102, 2.001, and -0.340, respectively. We
represented the summary operating point with a 95% prediction
region (Figure 5) and explored heterogeneity by differentiating
studies on the basis of antenatal screening for CHD, timing of
testing, type of oxygen saturation, study design, and risk of bias
for the “flow and timing” domain of QUADAS-2. We plotted
subgroups of studies in the ROC space.
Subgroup analysis and meta-regression
Table 2 summarizes results of the subgroup analysis including
sensitivity and false-positive rates.
Antenatal diagnosis
Four studies included newborn infants with antenatal screening
(Arlettaz 2006; Bhola 2014; Ewer 2011; Richmond 2002), and
15 studies did not (de-Wahl Granelli 2009; Gomez-Rodriguez
2015; Jones 2016; Klausner 2017; Koppel 2003; Meberg 2008;
Oakley 2015; Ozalkaya 2016; Riede 2010; Rosati 2005; Singh
2014; Turska 2012; VanNiekerk 2016; Zhao 2014; Zuppa 2015).
Summary estimates of sensitivity were 86.3% (95% CI 71.8 to
94.0) for studies that included antenatal screening, and 74.1%
(95% CI 65.7 to 81.1) for studies that did not include antenatal
screening. Summary estimates of specificity were 99.5% (95% CI
98.4 to 99.9) with a false-positive rate of 0.46% (95% CI 0.13
to 1.59) for studies with antenatal screening, and 99.9% (95%
CI 99.8 to 100) with a false positive rate of 0.10% (95% CI
0.05 to 0.21) for studies that did not include antenatal screening.
Sensitivity (P = 0.071) and specificity (P = 0.231) did not change
significantly when newborn infants with antenatal suspicion of
congenital heart defects were included compared with when they
were excluded.
Test timing
Eleven studies performed pulse oximetry screening after 24 hours
from birth (Bhola 2014; de-Wahl Granelli 2009; Klausner 2017;
Koppel 2003; Oakley 2015; Ozalkaya 2016; Riede 2010; Rosati
2005; VanNiekerk 2016; Zhao 2014; Zuppa 2015), and the other
eight studies performed pulse oximetry within 24 hours of birth
(Arlettaz 2006; Ewer 2011; Gomez-Rodriguez 2015; Jones 2016;
Meberg 2008; Richmond 2002; Singh 2014; Turska 2012). Sum-
mary estimates of sensitivity and specificity of studies that per-
formed screening after 24 hours were 73.6% (95% CI 62.8 to
82.1) and 99.9% (95% CI 99.9 to 100). For studies that per-
formed screening within 24 hours, summary estimates of sensitiv-
ity and specificity were 79.5% (95% CI 70.0 to 86.6) and 99.6%
(95%CI 99.1 to 99.8). Test timing to perform pulse oximetry had
no significant effect on sensitivity (P = 0.393), but the false-posi-
tive rate for detection of CCHD was lower when newborn pulse
oximetry was done after 24 hours from birth than when it was
done within 24 hours (0.06% [95% CI 0.03 to 0.13] vs 0.42%
[95% CI 0.20 to 0.89]; P = 0.027).
Limbs
Eleven studies used the foot alone (post-ductal) to measure oxygen
saturation (Arlettaz 2006; Bhola 2014; Gomez-Rodriguez 2015;
Koppel 2003;Meberg 2008;Oakley2015;Richmond 2002;Riede
2010; Rosati 2005; Turska 2012; Zuppa 2015); summary esti-
mates of sensitivity and specificity were 81.2% (95% CI 70.9 to
88.4) and 99.9% (95% CI 99.7 to 100), respectively, with a false-
positive rate of 0.13% (95% CI 0.05 to 0.31). Eight studies used
both right hand and foot (pre-ductal and post-ductal) (de-Wahl
Granelli 2009; Ewer 2011; Jones 2016; Klausner 2017; Ozalkaya
2016; Singh 2014; Van Niekerk 2016; Zhao 2014); summary es-
timates of sensitivity and specificity for this group of studies were
71.2% (95% CI 58.5 to 81.3) and 99.8% (95% CI 99.5 to 99.9),
respectively, with a false-positive rate of 0.17% (95% CI 0.06 to
0.46).We noted no significant differences in sensitivity (P = 0.197)
nor in specificity (P = 0.718) for pulse oximetry when measures
were obtained in the foot alone rather than in both the foot and
the right hand.
Risk of bias
We judged nine studies as having unclear risk of bias for the “flow
and timing” domain of QUADAS-2 (Arlettaz 2006; Bhola 2014;
Klausner 2017; Koppel 2003; Riede 2010; Rosati 2005; Turska
2012; Van Niekerk 2016; Zuppa 2015). Summary estimates of
sensitivity and specificity were 77.8% (95% CI 64.1 to 87.3) and
100% (95% CI 99.9 to 100), respectively, with a false-positive
rate of 0.05% (95% CI 0.02 to 0.12). We judged the remaining
10 studies as having low risk of bias (de-Wahl Granelli 2009; Ewer
2011;Gomez-Rodriguez 2015; Jones 2016;Meberg 2008;Oakley
2015; Ozalkaya 2016; Richmond 2002; Singh 2014; Zhao 2014);
summary estimates of sensitivity and specificity were 77.3% (95%
CI 68.8 to 84.0) and 99.7% (95% CI 99.3 to 99.8), respectively,
with a false-positive rate of 0.34% (95% CI 0.17 to 0.66). Risk
of bias for this domain had no significant effect on sensitivity (P
= 0.937), but studies judged as having unclear risk of bias for the
“flow and timing” domain had higher specificity (P = 0.016).
Sensitivity analysis
We performed a sensitivity analysis while excluding from the pri-
mary analysis studies with a threshold≤ 95% (Jones 2016; Koppel
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2003; Ozalkaya 2016; Riede 2010; Rosati 2005). For this analysis,
sensitivity and specificity were 78.1% (95% CI 71.2 to 83.7) and
99.8% (95% CI 99.6 to 99.9) with a false-positive rate of 0.23%
(95% CI 0.12 to 0.44). Exclusion of these studies increased the
sensitivity and false-positive rate of pulse oximetry screening.
We also performed a sensitivity analysis for which we added to
the primary analysis studies with a threshold ≤ 94% and < 96%
(Bakr 2005; Sendelbach 2008). For this analysis, sensitivity and
specificity were 77% (95% CI 70 to 82) and 100% (95% CI 100
to 100), respectively. Inclusion of these studies produced a slight
improvement in the sensitivity of the test.
Furthermore, we investigated the effects of potential sources of
bias by removing the four studies judged as having high risk of
bias in one of the QUADAS-2 domains (Arlettaz 2006; Oakley
2015; Van Niekerk 2016; Zuppa 2015). For this analysis, sensi-
tivity and specificity were similar to those in the main analysis,
at 75.5% (95% CI 68.2 to 81.6) and 99.79% (95% CI 99.7 to
99.9), respectively.
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Summary of findings
Should pulse oximetry be used to diagnose CCHD in asymptomatic newborns?
Patient or population: asymptomatic newborns at the t ime of pulse oximetry screening
Setting: hospital births
Index test: pulse oximetry
Reference test: Reference standards were both diagnost ic echocardiography (echocardiogram) and clinical follow-up in the f irst 28 days of lif e, including postmortem f indings
and mortality and congenital anomaly databases to ident if y false-negat ive pat ients
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CCHD: crit ical congenital heart defect; CI: conf idence interval
Sensitivity:
*We have downgraded certainty of the evidence from high to low because the low number of CCHD cases included in the review (serious imprecision) and secondly, there was a serious risk of
differential verification bias (ie, diagnosis was established by echocardiography in test positive cases however test negatives were usually confirmed by clinical follow-up or by accessing congenital
malformation registries and mortality databases).”
Certainty of the evidence (Balshem 2011)
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.




































































































D I S C U S S I O N
Summary of main results
For this review, we have identified and summarized the results
of all available cohort studies reporting the test accuracy of pulse
oximetry screening for detection of critical congenital heart defects
(CCHDs) in asymptomatic late preterm and full-term infants in
postnatal wards or well-baby nurseries. We have presented the
main results in Summary of findings.We analyzed data on457,202
participants from 21 included studies. We restricted the primary
analysis to studies with thresholds around 95% (< 95% and ≤
95%). Analysis, including 436,758 participants from 19 studies,
showed that pulse oximetry screening is a highly specific screening
test with moderate sensitivity and a low overall false-positive rate.
Overall sensitivity was 76.3%, specificity was 99.9%, and the false-
positive ratewas 0.14%. Summary positive andnegative likelihood
ratios were 535.6 and 0.24, respectively. Inclusion of studies that
used different saturation thresholds from those in the primary
analysis slightly improved the sensitivity of the test. Exclusion
of studies at high risk of bias did not significantly alter overall
sensitivity or specificity. Between-study heterogeneity was higher
in sensitivity than in specificity estimates.
Most studies were conducted in high-income countries (USA,
Europe); however, we also included studies from middle-income
countries, which increases the generalizability of review findings.
We noted methodological variation between studies with respect
to inclusion or exclusion of babies with a suspected antenatal diag-
nosis, timing of testing (before or after 24 hours of age), site of test-
ing (post-ductal only or pre-ductal and post-ductal), functional or
fractional saturation measurement, and study design (prospective
or retrospective). Subgroup analysis showed no effect on sensitiv-
ity or specificity among these variables, although later screening
was associated with a lower false-positive rate than was reported
with earlier screening.
The definition of CCHD provided in the published literature
is highly variable. We attempted to address this by applying a
strict definition (see above) to categorize CCHD in a standardized
manner, thus reducing the risk of an incorrect diagnosis.
Strengths and weaknesses of the review
Strengths of this review include a comprehensive literature search
performed to identify all relevant studies, rigorous assessment of
risk of bias of included studies using the QUADAS-2 tool, dupli-
cate data extraction, and performance of subgroup and sensitivity
analyses to investigate differences in estimates of accuracy of pulse
oximetry among studies with high, low, or unclear risk of bias.
However, only one study included more than 100 CCHD cases,
and 12 studies included fewer than 10 cases. The relatively low
number of CCHD cases included in this review indicates that the
precision of sensitivity is still low.
Our review has explored and quantified the heterogeneity, and re-
view authors have tried to identify possible sources of heterogene-
ity. Exploration of sources of heterogeneity has produced differ-
ent results for sensitivity and specificity. Sensitivity has not been
affected by any of the a priori selected sources of heterogeneity.
We cannot rule out the presence of unexplained heterogeneity in
this accuracy index, although it is highly likely that some of the
variability observed in sensitivities of individual studies could be
explained by the paucity of CCHD cases. Use of different strate-
gies for confirming pulse oximetry negative cases (ie, passively
with mortality or registry data rather than active clinical follow-
up) could well have introduced some degree of heterogeneity into
sensitivity results. However, this post hoc exploration was not per-
formed, given the scarcity of data. This means that sensitivity es-
timates are somewhat unstable with wide confidence intervals. At
the same time, this scarcity made analysis of heterogeneity under-
powered. Conversely, specificity was affected by the timing of the
test and by the risk of bias due to the flow and timing domain
of the QUADAS-2 tool. Statistical significance achieved by the
specificity analysis is a direct consequence of the large number of
healthy newborns included in the review. On the other hand, the
magnitude of differences between subgroup analyses was small.
False-positive rates were 0.06% and 0.42% for newborns screened
after and before 24 hours of birth, respectively. The absolute dif-
ference was 0.36% with more false-positives in the earlier screen-
ing group as compared with the late screening group. This means,
in relative terms, seven times more false positives are seen in the
earlier screening group than in the late screening group. Similarly,
false-positive rates varied between studies judged as having unclear
or low risk of bias for the “flow and timing” domain of QUADAS-
2 (ie, 0.05% vs 0.34% for unclear and low risk groups of studies,
respectively). The absolute difference a 0.29% reduction in false
positives in the unclear risk group, which equates almost seven
times fewer false positives in relative terms.
Agreements and disagreements with other studies or
reviews
This review includes more studies and a larger body of data from a
significantly greater number of infants than were included in simi-
lar previous systematic reviews of the test accuracy of pulse oxime-
try screening to detect CCHD (Mahle 2009; Thangaratinam
2007; Thangaratinam 2012), which reported identical statistical
methods and meta-analyses. Compared with the largest prior re-
view (Thangaratinam 2012), authors of this review screened a sig-
nificantly larger number of references (2695 vs 552) and included
data from over 220,000 more babies, allowing greater precision of
the estimates of test accuracy, and providing the most complete
meta-analysis available so far.
Overall sensitivity is similar (76.3% vs 76.5%) to that described
by Thangaratinam 2012 and is similar to the overall false-positive
18Pulse oximetry screening for critical congenital heart defects (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
rate (0.14% vs 0.14%). The statistically significant lower false-
positive rate between early and later screening persists (0.06% vs
0.42% and 0.05% vs 0.5%).
Applicability of findings to the review question
This review includes a large number of relevant studies that met
our inclusion criteria, and review authors had few concerns about
the relevance of their findings to our review questions. We mainly
judged included studies to be at low or unclear risk of bias in
QUADAS-2 domains. Most studies had a prospective design with
consecutive enrollment of participants and included an adequate
description of the index test. Some studies reported the exclusion
criteria poorly. Data were complete and were available for all in-
cluded studies.
Risk of differential verification bias was unavoidable as diagnosis
was established by echocardiography in test-positive cases; how-
ever, test-negative cases were usually confirmed by clinical follow-
up or by examination of congenital malformation registries and
mortality databases; risk of bias in the conduct or interpretation of
reference standard(s) was unclear in most studies that used incom-
plete reference standards. This of course raises the possibility that
some of the false negatives may be misclassified as true negatives.
This misclassification overestimates sensitivity and specificity. Dif-
ferential verification may have had an impact on the sensitivity
estimate. For this reason, along with the potential for imprecision,
given the small number of CCHD cases, we have downgraded
the GRADE certainty of evidence for sensitivity to “low.” In our
review, studies judged as having unclear risk of bias for the “flow
and timing” domain showed higher specificity.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review provides further compelling evidence for the use of
pulse oximetry as a routine screening test for early identification
of CCHD in asymptomatic babies in the well-baby nursery. The
test has high specificity and moderate sensitivity and meets the
criteria for universal screening.
Current evidence supports the introduction of routine screening
for CCHD in asymptomatic newborns before discharge from the
well-baby nursery. The test appears feasible in various middle-
income countries and shows consistent test accuracy.
Some important elements regarding specific screening algorithms
need further consideration. Data show no difference in sensitivity
based on the site of testing (pre-ductal or pre-ductal and post-
ductal). However, only two studies using pre-ductal and post-duc-
tal saturations reported absolute saturation values rather than just
test results (de-Wahl Granelli 2009; Ewer 2011). As has been re-
ported previously by Ewer 2016 and Thangaratinam 2012, sev-
eral CCHD cases that were detected by pre-ductal and post-ductal
testing would have been missed by post-ductal testing alone, but
the numbers are too small to affect sensitivity analysis results.
In addition, the finding of a lower false-positive rate with screening
after 24 hours needs to be balanced against the fact that many
countries discharge babies within 24 hours and - as is important
to note - most reported studies did not take into account the risk
that a baby with CCHDor other serious illness may present before
screening takes place (de-Wahl Granelli 2014; Ewer 2011; Ewer
2016; Riede 2010; Thangaratinam 2012).
The prevalence of CCHD is quite low, and most test-positive in-
fants do not have the target condition. The false-positive rate is
variable and depends largely on the timing of the screening (earlier
screening - within 24 hours of age - has a higher false-positive rate
than screening after 24 hours). This raises concerns that a false-
positive test may unnecessarily increase parental anxiety and may
lead to avoidable investigations and delayed discharge. Investiga-
tors in the UK PulseOx study assessed the acceptability of pulse
oximetry screening and reported on anxiety created by the test
- particularly among mothers of false-positive (FP) babies (Ewer
2012a; Powell 2013). Investigators quantified satisfaction with,
and perceptions of, the test and anxiety and depression following
screening by using validated questionnaires on samples of mothers
whose babies were true positive, false positive, and true negative.
All participants were predominantly satisfied with screening, and
it is important to note that mothers given false-positive results
after screening were no more anxious than those given true-nega-
tive results. Many studies report identification of alternative non-
cardiac conditions by pulse oximetry screening. Although these
conditions - such as congenital pneumonia and early-onset sepsis
- are technically false positives, their identification may be seen as
a positive additional benefit of screening; they are more likely to
be detected within the first 24 hours, allowing early treatment of
individuals with these potentially serious conditions. Healthcare
providers must consider the potential for overdiagnosis of these
conditions following screening and must apply rigorous criteria to
classify these conditions.
Implications for research
The large sample size of this review along with precise estimates
of sensitivity and specificity suggests that further research into
the accuracy of this screening method is unnecessary. In addition,
several countries, including the USA, have already implemented
screening. However, given concerns related to differential verifica-
tion, we propose that monitoring of screening outcomes (includ-
ing possible reduction in early mortality) and management of false
positives should be performed in a rigorous manner.
Further evidence regarding the routine screening of babies outside
19Pulse oximetry screening for critical congenital heart defects (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
the well-baby nursery (including non-intensive care unit [NICU]
stays and out-of-hospital births) is required. Additional raw satu-
ration data and further analysis are required to further elucidate
the relative sensitivities of post-ductal versus pre-ductal and post-
ductal saturation testing.
The ability of pulse oximetry to detect non-cardiac illness such as
respiratory and infectious conditions has been well described, but
test accuracy remains unclear.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arlettaz 2006
Study characteristics
Patient sampling Prospective multicenter study with consecutive enrollment of participants
Patient characteristics and set-
ting
Country: Switzerland
Setting: 4 hospitals inZurich: 3maternity hospitals and theDivision of Cardiology of theUniversity
Children’s Hospital
Study period: 1-year period (from May 13, 2003, to May 12, 2004)
Inclusion criteria: all newborn infants from 35 weeks’ gestation
Exclusion criteria:
Premature infants below 35 weeks’ gestation
Infants with a respiratory disorder
Live birth cohort, n = 3663 (401 infants excluded according to exclusion criteria)
N screened: 3262 (89%) (1764 at the University Hospital, 1011 at the Zollikerberg Hospital, 487
at the Triemli Hospital)
Gestational age: median: 39 weeks (range 35 to 42)
Prevalence of CCHD: 3.7 per 1000 live births
Index tests Pulse oximetry was performed with the Nellcor NPB-40 handheld pulse oximeter and the Nellcor
Max-N Oximax adhesive sensors
Screening protocol:
Site of testing: right or left foot
Test timing: within 24 hours (in 48 cases [1%], pulse oximetry was performed too early in part because
of immediate postnatal transfer to the cardiology unit or because patients were discharged before 6 hours
of age; in 255 cases (8%), pulse oximetry was performed after 12 hours; 2959 measurements [91%] were
performed at between 6 and 12 hours)
Oxygen saturation: functional
Threshold: < 95%
Measurement did not exceed 2 minutes. If saturation was below 95%, a senior house officer per-
formed a full clinical examination of the newborn. If the infant had saturation below 90% or any
signs suggestive of a CHD, echocardiography was performed immediately. In the case of an asymp-
tomatic newborn with borderline values (90% to 94%), a second measurement was performed 4 to
6 hours later
Target condition and reference
standard(s)
Target condition: Congenital heart disease was defined as the presence of a gross structural abnor-
mality of the heart or intrathoracic great vessels that is actually or potentially of functional signifi-
cance
Reference standard(s):
Reference standard used for positive pulse oximetry results: echocardiography (complete M-mode,
2-dimensional, and Doppler echocardiograms were performed either at the University Hospital with
an Acuson 128XP/10 [Siemens, Erlangen, Germany] with a 7.5-mHz transducer, or at the University
Children’s Hospital with a Sonos 5500 [Philips, Amsterdam, Netherlands], both equipped with all
Doppler modalities)
Reference standard used for negative pulse oximetry results: not stated
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Arlettaz 2006 (Continued)
Flow and timing Duration of follow-up: not stated




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Pulse oximetry
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
High Low
DOMAIN 4: Flow and Timing
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Arlettaz 2006 (Continued)
Were all patients included in the
analysis?
Yes
Was there at least 28 days of ap-
propriate follow up?
Unclear






Patient sampling Prospective study with consecutive enrollment of participants
Patient characteristics and set-
ting
Country: Saudi Arabia
Setting: neonatology department of King Abdel-Aziz Specialist Hospital
Study period: 6-month period (January 2004 to July 2004)
Inclusion criteria: asymptomatic newborns
Exclusion criteria:
Those admitted to the neonatal intensive care unit at birth
N screened: 5211
Prevalence of CCHD: 3.7 per 1000 live births
Index tests Pulse oximetry was performed with a Digioxi PO 920 pulse oximeter (Digicare Biomedical Tech-
nology, West Palm Beach, FL, USA)
Screening protocol:
Site of testing: right upper and lower limbs
Test timing: longer than 24 hours. Average age at screening was 31.7 hours
Oxygen saturation: fractional
Threshold: ≤ 94%
“Any infant who had an oxygen saturation < 90% from either limb was examined by echocardiography.
Saturations between 90% and 94% were verified by three readings; if they persisted in this range,
echocardiography was also done.”
Target condition and reference
standard(s)
Target condition: congenital heart disease
Reference standard(s):
Reference standard used for positive pulse oximetry results: echocardiography
Reference standard used for negative pulse oximetry results: cardiology service of the only pediatric
hospital in the region to identify patients who had received a diagnosis of CHD after discharge from
the well-baby nursery
Flow and timing Duration of follow-up: not stated
Loss to follow-up: none (n = 5211)
Comparative
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Pulse oximetry
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Were all patients included in the
analysis?
Yes
Was there at least 28 days of ap-
propriate follow up?
Unclear
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Bakr 2005 (Continued)






Patient sampling Retrospective observational study
Patient characteristics and set-
ting
Country: Australia
Setting: Royal Prince Alfred Hospital (tertiary maternity hospital delivering over 5000 newborns a
year)
Study period: 42-month period (from April 2008 to December 2011)
Inclusion criteria: all newborns (routine neonatal examination)
Exclusion criteria: not stated
Live birth cohort, n = 19,765
N screened: 18,801 (95.1%) (648 had been admitted to the nursery and did not qualify for
screening, 316 missed)
Prevalence of CCHD: 0.2 per 1000 live births
Index tests Pulse oximetry was performed with a Masimo Radical 5 portable oximeter (Masimo Corporation,
Irvine, CA, USA) with a reusable probe with disposable Coban tape (1-inch self-adherent wrap,
manufactured by 3M, Australia)
Screening protocol:
Site of testing: post-ductal (foot)
Test timing: longer than 24 hours (between 24 and 72 hours of life)
Oxygen saturation: functional
Threshold: < 95%
“If the post-ductal saturation was 95% or more, the result was assigned as a pass. Readings between 90%
and 95% led to a repeat saturation measurement in the next 1-2 hours. If the post-ductal saturation
remained below 95% on repeat testing, the newborn was referred for review and examination by a senior
neonatal paediatrician. If the saturation was less than 90%, at any time, the newborn was referred for
review by a senior neonatal paediatrician without waiting for a repeat test.”
Target condition and reference
standard(s)
Target condition: congenital heart disease
Reference standard(s):
Reference standard used for positive pulse oximetry results: echocardiography
Reference standard used for negative pulse oximetry results: database of the Heart Centre for Chil-
dren at Children’s Hospital at Westmead for any newborns undergoing cardiac surgery or catheter
intervention in the first year of life
Flow and timing Duration of follow-up: not stated
Loss to follow-up: 316missed (not performed by the resident, performed but not recorded, screening
not completed before early discharge or owing to compliance issues when the new protocol was
originally introduced)
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Pulse oximetry
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Were all patients included in the
analysis?
Unclear
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Bhola 2014 (Continued)
Was there at least 28 days of ap-
propriate follow up?
Unclear






Patient sampling Prospective study with consecutive enrollment of participants
Patient characteristics and set-
ting
Country: Sweden
Setting: 5 maternity units in West Götaland
Study period: July 2004 to March 31, 2007
Inclusion criteria: all newborn infants
Exclusion criteria:
Admitted to neonatal special care units
Live birth cohort, n = 46,963 (7064 excluded owing to rolling start of study or admission to neonatal
intensive care)
Eligible, n = 39,899 (Östran n = 13,455, Mölndaln n = 8953, Trollhättan n = 7019, Borås n =
5382, Skövde n = 5090)
Excluded, n = 1470 - refusal (19), oximeter failure (18), staff shortage (2), incomplete record of
screening results (39) or of physical examination (1392)
N screened: 38,429 (flowchart page 4)
Prevalence of CCHD: 0.7 per 1000 live births
Index tests Pulse oximetry was performed with a pulse oximeter Radical SET, version 4 (average time set on 8
seconds) with multisite LNOP YI sensors, Masimo, Irvine, CA, USA
Screening protocol:
Site of testing: pre-ductal (palm of right hand) and post-ductal (either foot)
Test timing: longer than 24 hours
Oxygen saturation: functional
Threshold: < 95%
“When both pre-ductal and post-ductal oxygen saturation was < 95% or the difference between the
two measurements was > 3% (≥ 2 standard deviations of interobserver measurement variability) the
baby was provisionally considered to be screening positive, but a repeat measurement was performed.
Babies with three repeated positive measurements were supposed to have an echocardiogram performed
the same day according to the study protocol, but with some babies scheduled for early discharge only two
pulse oximetry screenings were managed before the discharge examination was performed. Babies were
considered screening positive until a measurement not fulfilling screening positive criteria was obtained.
If saturation ≤ 90% the newborn was referred for an echocardiogram the same day.”
Target condition and reference
standard(s)
Target condition: congenital heart disease
Reference standard(s):
Reference standard used for positive pulse oximetry results: echocardiography
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de-Wahl Granelli 2009 (Continued)
Reference standard used for negative pulse oximetry results: mortality data of the National Board
of Forensic Medicine (information on all deaths due to undiagnosed cardiovascular malformations
in children younger than 1 year in Sweden born during the study)
Flow and timing Duration of follow-up: not stated





Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Pulse oximetry
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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de-Wahl Granelli 2009 (Continued)
Unclear Low
DOMAIN 4: Flow and Timing
Were all patients included in the
analysis?
No
Was there at least 28 days of ap-
propriate follow up?
Yes






Patient sampling Prospective multicenter study with consecutive enrollment of participants
Patient characteristics and set-
ting
Country: United Kingdom
Setting: 6 obstetrical units in the West Midlands
Study period: February 2008 to January 2009
Inclusion criteria: asymptomatic newborns (gestation > 34 weeks)
Study includes newborns in whom congenital heart defects were suspected antenatally after
midtrimester ultrasonography
Exclusion criteria:
Newborns with symptoms suggestive of cardiac disease that were detected before screening
Livebirth cohort, n = 26,513 (3768 missed, 2005 declined, 685 ineligible)
N screened: 20,055 (75.6%)
Prevalence of CCHD: 1.2 per 1000 live births
Index tests Pulse oximetry was performed with the Radical-7 pulse oximeter with reusable probe LNOP Y1
(Masimo, Irvine, CA, USA)
Screening protocol:
Site of testing: pre-ductal (right hand) and post-ductal (either foot in non-specified order)
Test timing: within 24 hours (median age at testing of 12.4 hours for the full cohort)
Oxygen saturation: functional
Threshold: < 95%
“A saturation of less than 95% in either limb or a difference of more than 2% between the limb saturation
readings (if both were ≥ 95%) was judged to be abnormal. Clinical examination was expedited if an
abnormal test result was obtained. If this examination was unremarkable, oximetry was repeated 1to 2
hours later. If abnormalities of the cardiovascular system were detected with expedited examination, or
saturations remained abnormal during a second test, the newborn were classified as test positive.”
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Ewer 2011 (Continued)
Target condition and reference
standard(s)
Target condition: critical congenital heart defects (ie, death or requiring invasive intervention before
28 days)
All infants with hypoplastic left heart, pulmonary atresia with intact ventricular septum, simple
transposition of the great arteries, or interruption of the aortic arch All infants dying or requiring
surgery within the first 28 days of life with coarctation of the aorta, aortic valve stenosis, pulmonary
valve stenosis, tetralogy of Fallot, pulmonary atresia with ventricular septal defect, or total anomalous
pulmonary venous connection
Reference standard(s):
Reference standard used for positive pulse oximetry results: echocardiography
Reference standard used for negative pulse oximetry results: clinical follow-up, use of cardiology
databases and congenital anomaly registries
Flow and timing Duration of follow-up: up to 12 months
Loss to follow-up: none (n analyzed: 20,055)
Comparative
Notes Funding: National Institute for Health Research Health Technology Assessment (NIHR HTA)
program (project number 06/06/03)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Pulse oximetry
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
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Ewer 2011 (Continued)
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Were all patients included in the
analysis?
Yes
Was there at least 28 days of ap-
propriate follow up?
Yes






Patient sampling Cross-sectional prospective study
Patient characteristics and set-
ting
Country: Mexico
Setting: Department of Neonatology, UMAE 48-Instituto Mexicano del Seguro Social (IMSS),
León, Gto
Study period: July 2010 to April 2011
Inclusion criteria: newborns > 6 hours of age in whom no CHD was suspected; only tested
consecutive newborns who were available during the working hours of investigators
Exclusion criteria:
newborns with lung disease
no informed consent
N screened: 1037
Gestational age: mean (SD): 38.9 (1.1) weeks
Prevalence of CCHD: 1.9 per 1000 live births
Index tests Pulse oximetry was performed with a Rad-5 handheld pulse oximeter with multisite sensor
Screening protocol:
Site of testing: left lower extremity (post-ductal)
Test timing: within 24 hours (mean age at pulse oximetry screening 12 hours - range 6 to 48 hours)
Oxygen saturation: functional
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Gomez-Rodriguez 2015 (Continued)
Threshold: < 95%
Measurement was taking during 2 minutes until the reading remained the same in 2 determinations
Target condition and reference
standard(s)
Target condition: critical congenital heart disease (no definition included)
Reference standard(s):
Reference standard used for positive pulse oximetry results: echocardiography
Reference standard used for negative pulse oximetry results: clinical records of all follow-up at 6
months
Flow and timing Duration of follow-up: 6 months




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No




DOMAIN 2: Index Test Pulse oximetry
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
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Gomez-Rodriguez 2015 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Were all patients included in the
analysis?
Yes
Was there at least 28 days of ap-
propriate follow up?
Yes






Patient sampling Retrospective observational study
Patient characteristics and set-
ting
Country: United Kingdom
Setting: neonatal intensive care unit, Northwick ParkHospital, Harrow,Middlesex (level-2 neonatal
unit without on-site access to pediatric echocardiography)
Study period: September 1, 2011, to August 31, 2013
Inclusion criteria: all newborns admitted to the neonatal unit during the study period
Exclusion criteria:
Antenatal diagnosis of CCHD
Admitted to neonatal intensive care unit after birth
Live birth cohort, n = 11,233 (973 neonatal unit admissions)
N screened: 10,260
Gestational age: not stated
Prevalence of CCHD: 0.2 per 1000 live births
Index tests Type of pulse oximeter not stated
Screening protocol:
Site of testing: both pre-ductal and post-ductal
Test timing: within 24 hours
Oxygen saturation: not stated
Threshold: ≤ 95% (or pre-ductal and post-ductal difference > 3%)
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Jones 2016 (Continued)
Target condition and reference
standard(s)
Target condition: critical congenital heart disease defined as CHD resulting in death or requiring
surgical intervention or therapeutic catheterization within the first 28 days of life
Reference standard(s):
Reference standard used for positive pulse oximetry results: echocardiography
Reference standard used for negative pulse oximetry results: National Congenital Heart Disease
Audit
Flow and timing Duration of follow-up: not stated




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Pulse oximetry
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
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of the results of the index tests?
Unclear Low
DOMAIN 4: Flow and Timing
Were all patients included in the
analysis?
Yes
Was there at least 28 days of ap-
propriate follow up?
Unclear






Patient sampling Retrospective observational study
Patient characteristics and set-
ting
Country: USA
Setting: 4 Yale-New Haven Health System hospitals in Connecticut
Study period: January 1 and December 31, 2014
Inclusion criteria: all newborns delivered during the study period
Exclusion criteria:
Live-born infants who died before CCHD screening
Antenatal screening
Live birth cohort, n = 10,589 (171 [1.6%] underwent an echocardiogram before screening, and 98
[0.9%] were not screened; 96 were missed in error and parents refused in 2 instances)
N screened: 10,320
Gestational age: 9584 (90.5%) were term (> 37 weeks)
Prevalence of CCHD: 0 per 1000 live births
Index tests Type of pulse oximeter not stated
Screening protocol:
Site of testing: both pre-ductal and post-ductal
Test timing: longer than 24 hours
Oxygen saturation: not stated
Threshold: < 95%
Target condition and reference
standard(s)
Target condition: critical congenital heart disease defined as structural defect associated with hy-
poxemia in the newborn period that requires surgical intervention before 1 year and, without inter-
vention, can lead to significant morbidity and mortality
Reference standard(s):
Reference standard used for positive pulse oximetry results: echocardiogram
Reference standard used for negative pulse oximetry results: follow-up
41Pulse oximetry screening for critical congenital heart defects (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Klausner 2017 (Continued)
Flow and timing Of 10,316 infants with negative pulse oximetry at the time of birth, possible to review postdischarge
records of only 52.1% (n = 5367)
Comparative
Notes Study was supported in part by a National Heart, Lung, and Blood Institute Medical Student
Research Fellowship, National Institutes of Health (award T35HL007649; to Ms Klausner), and
by grant UL1 TR001863 from the National Center for Advancing Translational Science at the
National Institutes of Health and the NIH Roadmap for Medical Research. Funded by the National
Institutes of Health (NIH)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Pulse oximetry
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Unclear Low
DOMAIN 4: Flow and Timing
Were all patients included in the
analysis?
Yes
Was there at least 28 days of ap-
propriate follow up?
Unclear






Patient sampling Prospective study with consecutive enrollment of participants
Patient characteristics and set-
ting
Country: USA
Setting: well infant nurseries at 2 hospitals (New York)
Study period: from May 1998 to November 1999
Inclusion criteria: all asymptomatic newborns
Exclusion criteria:
Admitted to neonatal special care units (infants who did manifest any of these clinical findings:
cyanosis, tachypnea [respiratory rate: 60/min], grunting, flaring, retraction, murmur, active pre-
cordium, or diminished pulses)
N screened: 11,281 (8642 at hospital A, 2639 at hospital B)
Prevalence of CCHD: 0.4 per 1000 live births
Index tests Pulse oximetry was performed with an Ohmeda Medical pulse oximeter
Screening protocol:
Site of testing: post-ductal
Test timing: longer than 24 hours. Timing of oximetry determination was linked to state-mandated
metabolic screening (24 hours of age) at hospital A. At hospital B, screening was performed imme-
diately before discharge as part of a series of discharge procedures (average length of stay for vaginal
delivery: 56.9 hours; for cesarean section: 103.2 hours)
Oxygen saturation: functional
Threshold: ≤ 95%
“single determination of post-ductal saturation”
Target condition and reference
standard(s)
Target condition: critical congenital cardiovascular malformation (CCVM) defined as a lesion that
would likely require surgical correction during the first month of life
Reference standard(s):
Reference standard used for positive pulse oximetry results: echocardiography
Reference standard used for negative pulse oximetry results: clinical follow-up and New York State
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Congenital Malformations Registry (CMR)
Flow and timing Duration of follow-up: not stated
Loss to follow-up: none (n analyzed = 11,281)
Comparative
Notes Study was supported by a cooperative agreement from the Centers for Disease Control and Preven-
tion
Oximeters were provided by Ohmeda Medical.
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Pulse oximetry
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
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DOMAIN 4: Flow and Timing
Were all patients included in the
analysis?
Yes
Was there at least 28 days of ap-
propriate follow up?
Unclear






Patient sampling Prospective multicenter study with consecutive enrollment of participants
Patient characteristics and set-
ting
Country: Norway
Setting: 14 hospitals with obstetrical departments and pediatric services and neonatal special or
intensive care units (50% of all deliveries in Norway)
Study period: 1-year period (2005 to 2006)
Inclusion criteria: healthy newborns
Exclusion criteria:
Prenatal diagnosis
Live birth cohort, n = 57,959 (not screened: 7951 [14%]; 224 of 7951 newborns [3%] had CHD)
N screened: 50,008 (86%)
Prevalence of CCHD: 0.7 per 1000 live births
Index tests Pulse oximetry was performed with a pulse oximeter type RAD-5v (Masimo Corporation, Irvine,
CA) with a multisite reusable sensor (LNOP YI)
Screening protocol:
Site of testing: post-ductal (foot)
Test timing: within 24 hours (first day)
Oxygen saturation: functional
Threshold: < 95%
“The probe was attached for at least 2 minutes, until a stable value was obtained. Retest if the result of
pulse-ox was < 95%.”
Target condition and reference
standard(s)
Target condition: congenital heart defects
Reference standard(s):
Reference standard used for positive pulse oximetry results: echocardiography
Reference standard used for negative pulse oximetry results: clinical follow-up
Flow and timing Duration of follow-up: 6 months after the last infants were born
Loss to follow-up: none (n analyzed: 50,008)
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Pulse oximetry
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Were all patients included in the
analysis?
Yes
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Was there at least 28 days of ap-
propriate follow up?
Yes






Patient sampling Prospective observational study
Patient characteristics and set-
ting
Country: United Kingdom
Setting: Tertiary Neonatal Unit from the Royal Gwent Hospital, Newport (3700 deliveries a year)
Study period: 2 years (from January 2007 to December 2009)
Inclusion criteria: all newborns at 35weeks’ gestation and above whowere admitted to the postnatal
ward
Exclusion criteria:
Admitted to the neonatal intensive care unit
Antenatal diagnosis of CHD
Births on weekends and holidays
Live birth cohort, n = 9613
N screened: 6329 (65.8%)
Gestational age of newborn infants included, range 35 to 42 weeks
Prevalence of CCHD: 1.3 per 1000 live births
Index tests Pulse oximetry was performed with a Nellcor NPB 40 pulse-oximeter (Pleasanton, CA) and a
reusable OXI-A/N saturation probe
Screening protocol:
Site of testing: post-ductal (foot)




“Newborns with saturation readings < 95% had a repeat reading taken on the other leg after thirty
minutes and if still < 95%, a further repeat reading after one hour. If the reading remained < 95%, it
was considered abnormal.”




Reference standard used for positive pulse oximetry results: echocardiography
Reference standard used for negative pulse oximetry results: regional pediatric cardiology database
and local death records
Flow and timing Duration of follow-up: not stated
Loss to follow-up: none (n analyzed: 6369)
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No




DOMAIN 2: Index Test Pulse oximetry
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Were all patients included in the
analysis?
Yes
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Oakley 2015 (Continued)
Was there at least 28 days of ap-
propriate follow up?
Unclear






Patient sampling Retrospective observational study
Patient characteristics and set-
ting
Country: Turkey
Setting: Bursa Sevket Yilmaz Training and Research Hospital
Study period: between January 2014 and December 2014
Inclusion criteria: asymptomatic newborns
Exclusion criteria:
Referred within first 24 hours of life or admitted to neonatal intensive care unit
Perinatal CCHD
Live birth cohort, n = 10,200 (excluded: hospitalized = 1100, referred = 890, perinatal CCHD = 2)
N screened: 8208
Gestational age: not stated
Prevalence of CCHD: 1 per 1000 live births
Index tests Pulse oximetry was performed with a Nellcor pulse oximeter.
Screening protocol:
Site of testing: both pre-ductal and post-ductal
Test timing: longer than 24 hours
Oxygen saturation: functional
Threshold: Screening test was considered positive in newborns whose saturation with pulse oximetry
was less than or equal to 95% and/or who had a difference < 3% between right lower and right
extremities
Target condition and reference
standard(s)
Target condition: CCHD defined as congenital heart disease requiring catheter-based or surgical
intervention within the first month of life, or causing high mortality and morbidity in the first
weeks of life
Reference standard(s):
Reference standard used for positive pulse oximetry results: echocardiography
Reference standard used for negative pulse oximetry results: echocardiography
Flow and timing Duration of follow-up: not stated
Loss to follow-up: none (n analyzed: 8208)
Comparative
Notes
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Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Pulse oximetry
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Were all patients included in the
analysis?
Yes
Was there at least 28 days of ap-
propriate follow up?
Unclear
Did all patients receive a refer-
ence standard?
Yes
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Patient sampling Prospective study with consecutive enrollment of participants
Patient characteristics and set-
ting
Country: United Kingdom
Setting: Sunderland Royal Hospital
Study period: from April 1, 1999, to March 31, 2001
Inclusion criteria: asymptomatic newborn without signs of respiratory or cardiac illness
Exclusion criteria:
Admitted to neonatal care units
Live birth cohort, n = 6166 (540 excluded: 447 neonatal unit, 5 no consent, 88 newborns missed)
N screened: 5626 (91%)
Prevalence of CCHD: 1.6 per 1000 live births
Index tests Pulse oximetry was performed with a radiometer Oxi machine.
Screening protocol:
Site of testing: post-ductal (foot)
Test timing: within 24 hours (after the age of 2 hours and before discharge)
Oxygen saturation: fractional
Threshold: < 95%
“Any baby who did not achieve a post-ductal fractional saturation of at least 95%was clinically examined
by the midwife. If no suspicions were raised by the examination, a second saturation measurement was
performed an hour or two later. If either the examination or the repeat saturation measurement were not
satisfactory, an echocardiogram was performed.”
Target condition and reference
standard(s)
Target condition: congenital cardiac malformation
Reference standard(s):
Reference standard used for positive pulse oximetry results: echocardiography
Reference standard used for negative pulse oximetry results: Regional Perinatal Mortality Survey
andNorthernCongenital Abnormality Survey &Diagnostic Database at FreemanHospital (referral
hospital)
Flow and timing Duration of follow-up: not stated




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Pulse oximetry
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Were all patients included in the
analysis?
Yes
Was there at least 28 days of ap-
propriate follow up?
Unclear
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Study characteristics
Patient sampling Prospective multicenter study with consecutive enrollment of participants
Patient characteristics and set-
ting
Country: Germany
Setting: primary, secondary, and tertiary care (34 neonatal/obstetrical departments in Saxony)
Study period: 2-year period (from July 2006 to June 2008)
Inclusion criteria: full-term and post-term neonates (gestational age ≥ 37 weeks)
Normal routine clinical examination
Informed parental consent
Exclusion criteria:
Antenatal diagnosis/suspicion of congenital heart disease
Livebirth cohort, n = 48,348 (excluded: 6108 newborns [72 clinical or prenatal diagnosis of CCHD;
6036 other])
N eligible for pulse oximetry screening: 42,240 (n = 727 [91%] did not receive pulse oximetry
screening, mainly because of early discharge after birth)
N screened: 41,445 (85.7%)
Prevalence of CCHD: 0.4 per 1000 live births
Index tests Pulse oximetry was performed with a great variety of devices (no further information)
Screening protocol:
Site of testing: post-ductal (foot)
Test timing: longer than 24 hours
Oxygen saturation: functional
Threshold: ≤ 95%
“The study protocol included repeated SpO2 measurements after 1 hour if the initial value was < 96%.”




Reference standard used for positive pulse oximetry results: echocardiography
Reference standard used for negative pulse oximetry results: Saxonian perinatal and neonatal reg-
istries
Flow and timing Duration of follow-up: not stated




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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DOMAIN 2: Index Test Pulse oximetry
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Were all patients included in the
analysis?
No
Was there at least 28 days of ap-
propriate follow up?
Unclear
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Study characteristics
Patient sampling Prospective study with consecutive enrollment of participants
Patient characteristics and set-
ting
Country: Italy
Setting: Perrino Hospital (referral center of the area)
Study period: from May 1, 2000, to November 30, 2004
Inclusion criteria: term newborns with uncomplicated neonatal courses
Exclusion criteria:
Infants who were symptomatic (ie, heart murmur, severe cyanosis)
Prenatal diagnosis of critical congenital cardiovascular malformation
N screened: 5292
Prevalence of CCHD: 0.6 per 1000 live births
Index tests Type of pulse oximeter not stated
Screening protocol:
Site of testing: post-ductal (foot)
Test timing: longer than 24 hours
Oxigen saturation: functional
Threshold: ≤ 95%
“Post-ductal saturation (SpO2) and the monitoring of oxymetry values were evaluated for two minutes
in each newborn.”
Target condition and reference
standard(s)
Target condition: CCHD defined as lesions requiring surgical correction or interventional proce-
dures during the first month of life
Reference standard(s):
Reference standard used for positive pulse oximetry results: echocardiography
Reference standard used for negative pulse oximetry results: clinical follow-up
Flow and timing Duration of follow-up: not stated




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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DOMAIN 2: Index Test Pulse oximetry
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Were all patients included in the
analysis?
Yes
Was there at least 28 days of ap-
propriate follow up?
Unclear






Patient sampling Prospective study with consecutive enrollment of participants
Patient characteristics and set-
ting
Country: USA
Setting: large public hospital (Parkland Health and Hospital System [PHHS]) in Dallas, TX, which
serves a primarily indigent Hispanic population)
Study period: from March 1, 2006, to February 28, 2007
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Sendelbach 2008 (Continued)
Inclusion criteria:
Term and late preterm neonates who did not have major malformations
Gestational age criteria: ≥ 35 weeks
Birth weight: ≥ 2100 grams
Exclusion criteria:
Admitted to neonatal intensive care unit (NICU)
Respiratory distress and/or cyanosis before 4 hours of age
Live birth cohort, n = 16,432 (excluded: 66 [0.4%]; 11 had CHD)
N screened: 15,233 (99.6%)
Prevalence of CCHD: 0.1 per 1000 live births
Index tests Pulse oximetry was performed with a Nellcor N-395 (Boulder, CO) pulse oximeter
Screening protocol:
Site of testing: post-ductal (foot)
Test timing: within 24 hours (4 hours after delivery)
Oxygen saturation: functional
Threshold: < 96%
“On the day of discharge, the 4-hour pulse oximetry result was made available to the provider. A pulse
oximetry result of 96% was considered normal and was not repeated. For neonates who failed to achieve
96% on the 4-hour screen, a follow-up pulse oximetry reading was performed by either the nursing staff or
the medical provider by using the procedure described above. When the discharge pulse oximetry reading
was < 96%, echocardiography was performed.”
Target condition and reference
standard(s)
Target condition: CCHD including cyanotic defects such as tetralogy of Fallot, pulmonary atresia,
truncus arteriosus, transposition of the great vessels, total anomalous pulmonary venous return, and
tricuspid atresia, as well as left-sided obstructive lesions, including coarctation of the aorta, critical
aortic stenosis, interrupted aortic arch, and hypoplastic left heart syndrome
Reference standard(s):
Reference standard used for positive pulse oximetry results: echocardiography
Reference standard used for negative pulse oximetry results: clinical follow-up
Flow and timing Duration of follow-up: not stated




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
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Unclear Low
DOMAIN 2: Index Test Pulse oximetry
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Were all patients included in the
analysis?
No
Was there at least 28 days of ap-
propriate follow up?
Unclear






Patient sampling Retrospective observational study
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Patient characteristics and set-
ting
Country: United Kingdom
Setting: level 3 Neonatal Unit of Birmingham Women’s Hospital
Study period: from April 1, 2010, to July 31, 2013
Inclusion criteria: screening is part of routine practice
Exclusion criteria:
Antenatal diagnosis of CCHD
N screened: 25,859
Prevalence of CCHD: 0.6 per 1000 live births
Index tests Pulse oximetry was performed with a handheld oximeter with a reusable probe
Screening protocol:
Site of testing: post-ductal (foot) and pre-ductal (right hand)
Test timing: within 24 hours
Oxygen saturation: functional
Threshold: < 95%
“A saturation result of < 95% in either limb or a difference of > 2% between the readings (if both were≥
95%) was considered abnormal. Following an abnormal first test, an initial assessment was performed.
If this was unremarkable, oximetry was repeated 1to 2 hours later. If the saturations remained abnormal
on second testing, or if there were concerns following the initial assessment, newborns were classified as
test positive and were admitted to the neonatal unit for further assessment.”




Reference standard used for positive pulse oximetry results: echocardiography
Reference standard used for negative pulse oximetry results: the Regional Cardiac Centre database at
BirminghamChildren’sHospital, the Regional Congenital Anomaly Register, and the localmortality
database
Flow and timing Duration of follow-up: not stated




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
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DOMAIN 2: Index Test Pulse oximetry
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Were all patients included in the
analysis?
Yes
Was there at least 28 days of ap-
propriate follow up?
Unclear






Patient sampling Prospective multicenter study with consecutive enrollment of participants
Patient characteristics and set-
ting
Country: Poland
Setting: 51 neonatal units in the Mazovian province of Poland as part of the POLKARD 2006 to
2008 program
Study period: 1 year (from January 16, 2007, to January 31, 2008)
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Inclusion criteria:
Protocol B: asymptomatic newborns at ≥ 34 weeks’ gestation
Exclusion criteria:
Circulatory symptoms or coexisting diseases
Prenatal diagnosis
Live birth cohort, n = 55,944 (in 2611 newborns, the test could not be performed owing to
technical problems [equipment failure, absence of trained staff due to holiday], 340 no consent,
1295 newborns with symptoms)
N screened: 51,698 (92.4%)
Prevalence of CCHD: 0.4 per 1000 live births
Index tests Pulse oximetry was performed with Novametrix, Nellcor, and Masimo pulse oximeters
Screening protocol:
Site of testing: post-ductal (foot)
Test timing: within 24 hours (between the 2nd and 24th hours of life)
Oxygen saturation: functional
Threshold: < 95%
“Themeasurement was carried out by specially trained nurses for 2 to 3 min on the infant’s lower extremity
between the 2nd and 24th hour of life after normalisation of the plethysmographic curve of the pulse
oximeter.”
Target condition and reference
standard(s)
Target condition: CCHD defined as requiring an interventional procedure or cardiac surgery in
the first month of life
Reference standard(s):
Reference standard used for positive pulse oximetry results: echocardiography
Reference standard used for negative pulse oximetry results: clinical follow-up or based on data from
the Mazovian Centre of Public Health
Flow and timing Duration of follow-up: not stated
Loss to follow-up: none (n analyzed: 51,698)
Comparative
Notes Funding: Ministry of Health in Poland
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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DOMAIN 2: Index Test Pulse oximetry
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Were all patients included in the
analysis?
Yes
Was there at least 28 days of ap-
propriate follow up?
Unclear






Patient sampling Prospective observational study
Patient characteristics and set-
ting
Country: South Africa
Setting: Mowbray Maternity Hospital (MMH), a busy level-2 maternity hospital in the Western
Cape Province, SA
Study period: May 19 to September 19, 2014
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Inclusion criteria: All neonates > 6 hours old with no clinical signs of cardiovascular disease were
eligible
Exclusion criteria: “unwell” infants, those < 6 hours old, those born to mothers < 14 years of age or
unable to give informed verbal consent (owing to illness, illiteracy, or language barriers); all infants
with a prenatal diagnosis of CHD or any signs of CHD, including a heart murmur (≥ 3/6) or
significant dysmorphic features
Livebirth cohort, n = 2256 (1220 mothers not approached)
N screened: 1001 (44%)
Prevalence of CCHD: 1 per 1000 live births
Index tests Pulse oximetry was performed with Nellcor pulse oximeters.
Screening protocol:
Site of testing: right hand and any foot
Test timing: longer than 24 hours
Oxygen saturation: functional
Threshold: < 95%
Target condition and reference
standard(s)
Target condition: CCHD, which leads to death or needs surgical intervention before 28 days
Reference standard(s):
Reference standard used for positive pulse oximetry results: echocardiography
Reference standard used for negative pulse oximetry results: not stated
Flow and timing Duration of follow-up: no physical follow-up
Loss to follow-up: none (n analyzed: 1001)
Comparative
Notes Study was funded in part by the School of Child and Adolescent Health Research Committee,
Department of Paediatrics, Red Cross War Memorial Children’s Hospital and University of Cape
Town
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No




DOMAIN 2: Index Test Pulse oximetry
If a threshold was used, was it
pre-specified?
Yes
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Van Niekerk 2016 (Continued)
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
High Low
DOMAIN 4: Flow and Timing
Were all patients included in the
analysis?
Yes
Was there at least 28 days of ap-
propriate follow up?
No






Patient sampling Prospective multicenter study with consecutive enrollment of participants




Study period: from August 1, 2011, to November 30, 2012
Inclusion criteria: all consecutive newborns (irrespective of gestational age or neonatal intensive
care unit status)
Exclusion criteria:
Prenatally diagnosed major CHD
Livebirth cohort, n = 130,282 (not screened: 9575 [3571 incomplete screening data, 1450 lack of
consent, 2496 transfer to superior hospital, 27 prenatally diagnosedmajorCHD, 2031 symptomatic
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newborns])
N screened: 120,707 (92.7%)
Prevalence of CCHD: 1.2 per 1000 live births
Index tests Pulse oximetry was performed with a RAD-5V / Multisite reusable sensor (LNOP YI, Masimo)
Screening protocol:
Site of testing: pre-ductal (right hand) and post-ductal (foot)
Test timing: longer than 24 hours
Oxygen saturation: functional
Threshold: < 95%
“The clinician repeated pulse oximetry testing 4 hours later if the first pulse oximeter oxygen saturation
measurement was between 90% and 95%. Screening was deemed positive if an SpO2 of less than 95%
was obtained both on the right hand and on either foot on two measures, separated by 4 hours; a difference
between the two extremities was more than 3% on two measures, separated by 4 hours; or any measure
was less than 90%.”




Reference standard used for positive pulse oximetry results: echocardiography
Reference standard used for negative pulse oximetry results: clinical follow-up and parents’ feedback
Flow and timing Duration of follow-up: clinical examination at 6 weeks of age at the hospital
“The Children’s Hospital of Fudan University provided help with further confirmation of diagnosis for
all affected babies from the participating hospitals. All cases of congenital heart disease were followed up
by telephone review at least 1 year of age.”
Loss to follow-up: none (n analyzed: 120,707)
Comparative
Notes Funding: Key Clinical Research Project sponsored by Ministry of Health, Shanghai Public Health
Three-Year Action Plan, sponsored by Shanghai Municipal Government, and National Basic Re-
search Project of China
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Pulse oximetry
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If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Were all patients included in the
analysis?
Yes
Was there at least 28 days of ap-
propriate follow up?
Yes






Patient sampling Prospective study with consecutive enrollment of participants
Patient characteristics and set-
ting
Country: Italy
Setting: Agostino Gemelli General Hospital
Study period: 2 years (from 2009 to 2010)
Inclusion criteria: all newborns admitted to the nursery. These newborns by definition were consid-
ered healthy or were under observation for maternal disease, mild prematurity, or low birth weight
Exclusion criteria:
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Newborns with syndrome
Total number of newborn infants included:
N screened: 5750
Prevalence of CCHD: 0.2 per 1000 births
Index tests Pulse oximetry was performed with an Ohmeda 3900 pulse oximeter
Screening protocol:
Site of testing: post-ductal (foot)
Test timing: longer than 24 hours
Oxygen saturation: functional
Threshold: < 95%
“Themeasurement was performedby a professional nurse in all newborns admitted to the nursery, between
the 48th and 72nd hours of life, before discharge. The probe detector was placed on one of the two legs,
making sure that the newborn was quiet and with warm ends. The measurement was performed in
presence of stable, continuous and free of artefacts pulse wave, for at least 3 minutes. In case of positive
screening, a second check was carried out by medical staff after 15 to 30 min.”
Target condition and reference
standard(s)
Target condition: CCHD defined as severe cardiac alterations that require cardiac surgery during
the first year of life
Reference standard(s):
Reference standard used for positive pulse oximetry results: electrocardiographic and echocardiog-
raphy (echocardiograph “HP Sonos 4500, Agilent Technologies” [Andover, MA], a multifrequency
probe [5 to 12 MHz], suitable for study of the neonatal heart. Evaluation was performed by 2-
dimensional analysis [2-D], analysis of M-mode, and Doppler ultrasound)
Reference standard used for negative pulse oximetry results: not stated
Flow and timing Duration of follow-up: not stated




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Pulse oximetry
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If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
High Low
DOMAIN 4: Flow and Timing
Were all patients included in the
analysis?
Yes
Was there at least 28 days of ap-
propriate follow up?
Unclear




CCHD: critical congenital heart defect.
CHD: congenital heart defect.
NICU: neonatal intensive care unit.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Andrews 2014 Study includes only information about positive results. Investigators did not follow infants who passed the
screen once they left the hospital
Ewer 2012a Health Technology Assessment report on already included study
Hoke 2002 Case-control design
John 2016 Study includes only information about positive results.
Kardasevic 2016 Different population (not asymptomatic newborns)
Kochilas 2013 Different outcome (not accuracy)
Lhost 2014 Out-of-hospital births
Meberg 2009 Different outcome (not accuracy)
Movahedian 2016 Study includes only information about positive results.
Narayen 2016a Out-of-hospital births
Prudhoe 2013 Study did not include enough information for construction of a 2 × 2 table. Study includes data contained
in Richmond 2002 (study included)
Reich 2003 Study provides a partial 2 × 2 diagnostic table from which estimation of sensitivity was not possible
Reich 2008 Different outcome (not accuracy)
Reich 2008a Different outcome (not accuracy)
Riede 2009 Preliminary study
Ruangritnamchai 2007 Study includes only information about positive results.
Saha 2014 Journal club
Saxena 2015 Different population (not asymptomatic newborns)
Schena 2017 Different index test (combined pulse oximetry and perfusion index)
Studer 2014 Different outcome (not accuracy)
Taksande 2013 Study includes only information about positive results. Definition of test positive was not given
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Tautz 2010 No ability to determine CCHD outcomes
Tsao 2016 Study includes only information about positive results.
Vaidyanathan 2011 Study provides a partial 2 × 2 diagnostic table. No ability to determine CCHD outcomes
Valmari 2006 Case report
Walsh 2011 Different outcome (not accuracy)
CCHD: critical congenital heart defect.
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D A T A
Presented below are all the data for all of the tests entered into the review.






1 All studies 21 457202
2 Primary analysis (threshold <
95% or ≤ 95%)
19 436758
Test 1. All studies.
Review: Pulse oximetry screening for critical congenital heart defects
Test: 1 All studies
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Arlettaz 2006 12 12 0 3238 1.00 [ 0.74, 1.00 ] 1.00 [ 0.99, 1.00 ]
Bakr 2005 3 2 0 5206 1.00 [ 0.29, 1.00 ] 1.00 [ 1.00, 1.00 ]
Bhola 2014 4 26 0 18771 1.00 [ 0.40, 1.00 ] 1.00 [ 1.00, 1.00 ]
de-Wahl Granelli 2009 19 68 10 39724 0.66 [ 0.46, 0.82 ] 1.00 [ 1.00, 1.00 ]
Ewer 2011 18 177 6 19854 0.75 [ 0.53, 0.90 ] 0.99 [ 0.99, 0.99 ]
Gomez-Rodriguez 2015 2 12 0 1023 1.00 [ 0.16, 1.00 ] 0.99 [ 0.98, 0.99 ]
Jones 2016 2 21 0 10237 1.00 [ 0.16, 1.00 ] 1.00 [ 1.00, 1.00 ]
Klausner 2017 0 4 1 10315 0.0 [ 0.0, 0.97 ] 1.00 [ 1.00, 1.00 ]
Koppel 2003 3 1 2 11275 0.60 [ 0.15, 0.95 ] 1.00 [ 1.00, 1.00 ]
Meberg 2008 27 297 8 49676 0.77 [ 0.60, 0.90 ] 0.99 [ 0.99, 0.99 ]
Oakley 2015 7 7 1 6314 0.88 [ 0.47, 1.00 ] 1.00 [ 1.00, 1.00 ]
Ozalkaya 2016 6 1 4 8197 0.60 [ 0.26, 0.88 ] 1.00 [ 1.00, 1.00 ]
Richmond 2002 8 56 1 5561 0.89 [ 0.52, 1.00 ] 0.99 [ 0.99, 0.99 ]
Riede 2010 14 40 4 41384 0.78 [ 0.52, 0.94 ] 1.00 [ 1.00, 1.00 ]
Rosati 2005 2 1 1 5288 0.67 [ 0.09, 0.99 ] 1.00 [ 1.00, 1.00 ]
Sendelbach 2008 1 24 0 15208 1.00 [ 0.03, 1.00 ] 1.00 [ 1.00, 1.00 ]
Singh 2014 9 199 6 25645 0.60 [ 0.32, 0.84 ] 0.99 [ 0.99, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
(Continued . . . )
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Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Turska 2012 15 14 4 51665 0.79 [ 0.54, 0.94 ] 1.00 [ 1.00, 1.00 ]
Van Niekerk 2016 1 1 1 998 0.50 [ 0.01, 0.99 ] 1.00 [ 0.99, 1.00 ]
Zhao 2014 122 394 24 120167 0.84 [ 0.77, 0.89 ] 1.00 [ 1.00, 1.00 ]
Zuppa 2015 0 3 1 5747 0.0 [ 0.0, 0.97 ] 1.00 [ 1.00, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 2. Primary analysis (threshold < 95% or ≤ 95%).
Review: Pulse oximetry screening for critical congenital heart defects
Test: 2 Primary analysis (threshold < 95% or≤ 95%)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Arlettaz 2006 12 12 0 3238 1.00 [ 0.74, 1.00 ] 1.00 [ 0.99, 1.00 ]
Bhola 2014 4 26 0 18771 1.00 [ 0.40, 1.00 ] 1.00 [ 1.00, 1.00 ]
de-Wahl Granelli 2009 19 68 10 39724 0.66 [ 0.46, 0.82 ] 1.00 [ 1.00, 1.00 ]
Ewer 2011 18 177 6 19854 0.75 [ 0.53, 0.90 ] 0.99 [ 0.99, 0.99 ]
Gomez-Rodriguez 2015 2 12 0 1023 1.00 [ 0.16, 1.00 ] 0.99 [ 0.98, 0.99 ]
Jones 2016 2 21 0 10237 1.00 [ 0.16, 1.00 ] 1.00 [ 1.00, 1.00 ]
Klausner 2017 0 4 1 10315 0.0 [ 0.0, 0.97 ] 1.00 [ 1.00, 1.00 ]
Koppel 2003 3 1 2 11275 0.60 [ 0.15, 0.95 ] 1.00 [ 1.00, 1.00 ]
Meberg 2008 27 297 8 49676 0.77 [ 0.60, 0.90 ] 0.99 [ 0.99, 0.99 ]
Oakley 2015 7 7 1 6314 0.88 [ 0.47, 1.00 ] 1.00 [ 1.00, 1.00 ]
Ozalkaya 2016 6 1 4 8197 0.60 [ 0.26, 0.88 ] 1.00 [ 1.00, 1.00 ]
Richmond 2002 8 56 1 5561 0.89 [ 0.52, 1.00 ] 0.99 [ 0.99, 0.99 ]
Riede 2010 14 40 4 41384 0.78 [ 0.52, 0.94 ] 1.00 [ 1.00, 1.00 ]
Rosati 2005 2 1 1 5288 0.67 [ 0.09, 0.99 ] 1.00 [ 1.00, 1.00 ]
Singh 2014 9 199 6 25645 0.60 [ 0.32, 0.84 ] 0.99 [ 0.99, 0.99 ]
Turska 2012 15 14 4 51665 0.79 [ 0.54, 0.94 ] 1.00 [ 1.00, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
(Continued . . . )
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Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Van Niekerk 2016 1 1 1 998 0.50 [ 0.01, 0.99 ] 1.00 [ 0.99, 1.00 ]
Zhao 2014 122 394 24 120167 0.84 [ 0.77, 0.89 ] 1.00 [ 1.00, 1.00 ]
Zuppa 2015 0 3 1 5747 0.0 [ 0.0, 0.97 ] 1.00 [ 1.00, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Main studies characteristics





















functional < 95% echocardiog-
raphy
NA
















































excluded Radical-5 post-ductal within 24
hours
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Table 1. Main studies characteristics (Continued)




































excluded RAD-5v post-ductal within 24
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Riede 2010 excluded NA post-ductal longer than
24 hours




Rosati 2005 excluded NA post-ductal longer than
24 hours
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Table 1. Main studies characteristics (Continued)


















functional < 95% echocardiog-
raphy
NA
































Included 4 86.3% (71.8 to 94.0) 0.071 0.46% (0.13 to 1.59) 0.231




11 73.6% (62.8 to 82.1) 0.393 0.06% (0.03 to 0.13) 0.027
Within 24 hours 8 79.5% (70.0 to 86.6) 0.42% (0.20 to 0.89)
Limb
Foot only 11 81.2% (70.9 to 88.4) 0.197 0.13% (0.05 to 0.31) 0.718
Foot and right hand 8 71.2% (58.5 to 81.3) 0.17% (0.06 to 0.46)
Risk of bias (“flow
and timing”)
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Table 2. Subgroup analysis (Continued)
Unclear risk of bias 9 77.8% (64.1 to 87.3) 0.937 0.05% (0.02 to 0.12) 0.016
Low risk of bias 10 77.3% (68.8 to 84.0) 0.34% (0.17 to 0.66)
A P P E N D I C E S
Appendix 1. Searches performed
Date: March 2017 Search strategy Hits retrieved
Cochrane Central Register of Controlled
Trials (CENTRAL; 2017, Issue 2) in the
Cochrane Library
(infant or newborn or neonate or neonatal
or premature or preterm or very low birth
weight or low birth weight or VLBW or
LBW)
AND(CongenitalHeartDefectsORHeart
Valve Diseases OR tetralogy near fallot*
OR cyanotic near heartOR congenital near
heart OR congenital near cardiac OR aor-
tic near coarctation OR valve near diseases
OR hypoplastic near syndrome OR pul-
monary near atresia OR interruption of the
aortic arch OR valve near stenosis OR pul-
monary near atresia) AND (oximetry OR
pulse near oximetr* OR oxygen near satu-
ration OR O2 near saturation)
76
MEDLINE via PubMed (1966 to current) (Infant, Newborn[MeSH] OR neonate*
OR infant* OR newborn)* AND (Heart
Defects, Congenital[MeSH] OR Heart
Valve Diseases[MeSH] OR tetralogy fal-
lot* OR cyanotic heart OR congenital
heart OR congenital cardiac OR aortic
coarctation OR valve diseases OR hy-
poplastic syndrome OR pulmonary atre-
sia OR interruption of the aortic arch OR
valve stenosis OR pulmonary atresia) AND
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Embase via Ovid (1980 to current) (exp Infant OR expNewborn OR neonat*.
mp OR infant*.mp OR newborn*.mp)
AND ((exp congenital heart malforma-
tion/) OR (exp valvular heart disease/)
OR (tetralogy adj3 fallot*).mp OR (cyan-
otic adj3 heart).mp OR (congenital adj3
heart).mp OR (congenital adj3 cardiac).
mp OR (aortic adj3 coarctation).mp OR
(valve adj3 diseases).mp OR (hypoplas-
tic adj3 syndrome).mp OR (pulmonary
adj3 atresia).mp OR (interruption of the
aortic arch).mp OR (valve adj3 stenosis).
mp) AND (exp oximetry OR (pulse adj3
oximetr*).mpOR (oxygen adj3 saturation)
.mp OR (O2 adj3 saturation).mp)
1779
CINAHL (1982 to current) TX (Infant,NewbornORneonate*OR in-
fant* OR newborn*) AND TX (Congeni-
tal Heart Defects ORHeart Valve Diseases
OR tetralogy fallot*OR cyanotic heartOR
congenital heartOR congenital cardiacOR
aortic coarctation OR valve diseases OR
hypoplastic syndromeORpulmonary atre-
sia OR interruption of the aortic arch OR
valve stenosis OR pulmonary atresia) AND
TX (oximetry OR pulse oximetr* OR oxy-
gen saturation OR O2 saturation)
192
TOTAL before de-duplication 3415
TOTAL after de-duplication 2695
Appendix 2. QUADAS 2
Item Criteria for assessment
Domain 1: Patient selection
Describe methods of patient selection (prior testing, presentation, intended use of index test and setting)
A. Risk of bias
Was a consecutive or random sample of patients enrolled? “Yes” if described enrolling a consecutive or random sample of
newborns before discharge from hospital
“No” if criteria for “yes” not achieved
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“Unclear” if the study did not describe the method of enrollment
Did the study avoid inappropriate exclusions? “Yes” if exclusions were detailed and review authors reached con-
sensus on the appropriateness of any exclusion
“No” if inappropriate exclusions were reported (eg, if cases with
antenatally diagnosed congenital heart disease were excluded)
“Unclear” if insufficient information was provided
Could selection of patients have introduced bias? A judgment of low, high, or unclear risk of bias was based on a
balanced assessment of responses to the above signaling questions
B. Concerns about applicability
Is there concern that the included patients do notmatch the review
question?
A judgment of low, high, or unclear concern about applicability
was made on the basis of how closely the sample matches an
asymptomatic newborn population screened for CCHD
Domain 2: Index test
Describe the index test and how it was conducted and interpreted
A. Risk of bias
Were the index test results interpreted without knowledge of re-
sults of the reference standard?
“Yes” if pulse oximetry was conducted and interpreted before the
echocardiogram or clear temporal pattern to the order of testing
that precludes the need for formal blinding (eg, echocardiogram,
clinical follow-up, and inclusion in congenital anomaly registries
are always posterior to index test)
“No” if reference standard results were available to those who
conducted or interpreted the pulse oximetry
“Unclear” if insufficient information was provided
If a threshold was used, was it prespecified? “Yes” if a threshold was prespecified
“No” if trial authors selected a cutoff value based on analysis of
collected data
“Unclear” if insufficient information was provided
Could the conduct or interpretation of the index test have intro-
duced bias?
A judgment of low, high, or unclear risk of bias was based on a
balanced assessment of responses to the above signaling questions
B. Concerns about applicability
Is there concern that the index test, its conduct, or its interpreta-
tion differ from the review question?
A judgment of low, high, or unclear concern about applicability
was based on a balanced assessment of information detailed under
“index test” description
Domain 3: Reference standard
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Describe the reference standard(s) and how they were conducted and interpreted
A. Risk of bias
Is the reference standard likely to correctly classify the target con-
dition?
“Yes” if the study used an appropriate reference standard (diagnos-
tic echocardiography and clinical follow-up in the first 28 days of
life, including postmortem findings and mortality and congenital
anomaly databases to identify false-negative patients)
“No” if the study did not use an appropriate reference standard
“Unclear” if the reference standard used was not clearly specified
Were the reference standard results interpretedwithout knowledge
of results of the index test?
“Yes” if the person undertaking the reference test did not know
the results of the pulse oximetry
“No” if pulse oximetry results were available to those who con-
ducted or interpreted the echocardiogram
“Unclear” if insufficient information was provided
Could the reference standard, its conduct, or its interpretation
have introduced bias?
A judgment of low, high, or unclear risk of bias was based on a
balanced assessment of responses to the above signaling questions
B. Concerns about applicability
Is there concern that the target condition as defined by the refer-
ence standard does not match the question?
A judgment of low, high, or unclear concern about applicability
was based on the possibility of reference standards mixing both
critical and non-critical congenital heart disease
Domain 4: Flow and timing
Describe any patients who did not receive the index test and/or reference standard(s) or who were excluded from the two-by-two
table (refer to flow diagram), and describe the time interval and any interventions between index test and reference standard(s)
A. Risk of bias
Was at least 28 days of appropriate follow-up provided? “Yes” if follow-up was at least 28 days
“No” if follow-up was less than 28 days
“Unclear” if insufficient information was provided
Did all patients receive a reference standard? “Yes” if the study specifically stated that all patients received
echocardiogram, clinical follow-up, or confirmation by mortality
and congenital anomaly databases (for both positive and negative
pulse oximetry results)
“No” if some negative pulse oximetry participants were lost to
follow-up without any confirmation
“Unclear” if insufficient information was provided
Were all patients included in the analysis? “Yes” if the study had no withdrawals or withdrawals were clearly
described
“No” if the number of patients contributing to the two-by-two
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tables did not match the number of patients recruited and no
reasons for exclusions were described
“Unclear” if information was not enough to establish the flow of
participants
Could the patient flow have introduced bias? A judgment of low, high, or unclear risk of bias was based on a
balanced assessment of responses to the above signaling questions
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Searching other resources
The protocol describes our plan to search the MEDION database (www.mediondatabase.nl), but this resource is not longer available.
Statistical analysis
We planned to use a 95% saturation level as the primary threshold for the analysis and to perform separate analyses for other thresholds
categorized as < 95% and > 95% saturation levels. However, at editorial phase, it was suggested to group thresholds. As many studies
used a lower than or lower than or equal to 95% threshold, we decided to group all these studies for the main analysis.
The protocol describes our plan to switch the modeling strategy to fit two univariate random-effects logistic regression models by
assuming no correlation between sensitivity and specificity if the number of studies was small (fewer than four), or if the proposed
modeling strategy led to problems in achieving convergence. We identified sufficient studies to fit a bivariate model and had no problem
achieving model convergence.
Certainty of the evidence
We decided post hoc to assess the certainty of evidence using the Grading of Recommendations Assessment, Development and
Evaluation (GRADE) approach (Schunemann 2008).
Subgroup analysis
We did not perform subgroup analyses by oxygen saturation or study design, given the low power of these subgroup analyses.
Sensitivity analysis
Additionally, we decided to perform ad hoc sensitivity analyses to describe how sensitivity and specificity vary by including or excluding
studies with different thresholds.
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